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Stroke is the second leading cause of death [1] as well as the most common
cause of disability and second most common cause of dementia worldwide [2].
Stroke has a tremendous impact on economy, society and healthcare: in the U.S.
only, 7 million individuals are affected, which translates into 3% of the entire pop-
ulation. The costs caused by stroke in the U.S. are estimated to be around 60
billion dollars per year [3]. ’Approximately 795,000 strokes occur in the United
States each year’ [4]. Stroke risk increases remarkably with age: the incidence
of stroke in 35- to 44-year-olds is 30-120 in 100,000 per year, while it increases
to 670-970 in 100,000 per year in 65- to 74-year-olds. Due to increasing efforts in
prevention and awareness of vascular risk factors, incidence rates in highly devel-
oped countries have been decreasing over the past decade [5], while they are still
increasing in developing countries [6]. With the aging of population especially in
Western countries and constant development in low-income countries that results
in higher life expectancy, stroke rates are expected to increase drastically over the
course of the next decade. It is estimated that in the U.S., a death due to stroke
occurs every 4 minutes [7]. The one-month fatality is around 12% for ischemic
stroke, while the mortality of hemorrhagic stroke is much higher (33-45%) [8].
Relatively speaking, stroke mortality is higher in men, but in absolute numbers,
more women die from a stroke because of the higher life expectancy in women
[7].
1.1.1 Risk factors
Risk factors for stroke include demographic factors such as age, sex and heredity
[9]. According to the INTERSTROKE study, which involved about 25,000 subjects
in 32 countries, cardiovascular diseases, diabetes mellitus, diet and physical ac-
tivity, and toxic habits such as smoking and alcohol abuse are major factors that
contribute to the population-attributable risk [10]. Hypertension is the single most
important risk factor in this group [10, 11]. Cardiac diseases, mainly atrial fibril-
lation and coronary artery disease, are another major risk factor, particularly for
ischemic strokes [12]. Diabetes mellitus doubles the risk for an ischemic stroke
[13], and it is considered one of the most important risk factors especially because
of its atherogenic complications and high prevalence in the population. The same
applies for dyslipidemia [11]. Approximately 18% of all strokes can be attributed
to active cigarette smoking [11].
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1.1.2 Stroke etiology
Approximately 87% of all strokes are ischemic strokes, 10% are hemorrhagic
strokes and subarachnoid hemorrhages account for 3% [14]. Ischemic strokes
can be characterized as either thrombotic (macroangiopathic or microangio-
pathic), embolic (with cardiac or arterial origin), or as a result of systemic hypop-
erfusion (watershed area stroke) [15]. Ischemic strokes can be categorized by
the TOAST Classification (Trial of Org 10172 in Acute Stroke Treatment) that was
established in 1993 [16]. This classification defines five subtypes: large-artery
atherosclerosis, cardioembolism, small-vessel occlusion, other determined etiol-
ogy or undetermined etiology [16]. Ischemic stroke patients are diagnosed and
classified based on brain imaging (computed tomography (CT) and/or magnetic
resonance imaging (MRI)), cardiac exams (electrocardiogram (ECG), echocardio-
graphy), duplex sonography of extracranial arteries, angiography, and laboratory
analyses.
Atherosclerotic changes are the major pathophysiological process that lead to
a stroke. Lipid-filled macrophages (so-called foam cells) accumulate in the in-
tima, causing gross changes such as yellowish, fatty streaks in the endothelium
of vessels [17]. Lesions may progress to massive extracellular lipid accumula-
tions and complicated fibrous plaques, which are composed of a cap of smooth
muscle cells and collagen covering the lipid area in the vessel. Main risk factors
for atherosclerosis include hypertension, hypercholesterolemia, cigarette smok-
ing and diabetes mellitus [18]. In an atherosclerotic plaque, several processes
lead to an inflammatory response by invasion of monocytes and T-lymphocytes.
The plaque can destabilize and rupture, exposing subendothelial collagen which
causes platelet activation [19, 20]. Platelet activation can also be caused by shear
stress conditions in atherosclerosis. Endothelial injury also leads to activation of
the extrinsic pathway of the coagulation cascade, which enhances formation of a
thrombus [21]. Thrombus formation can result in a partial or permanent reduction
of blood flow by occluding a brain vessel, resulting in a transient ischemic attack
(TIA) or an ischemic stroke, respectively [18]. The thrombus can also separate
from the primary atherosclerotic site and occlude a smaller downstream vessel,
which is defined as an embolic stroke. Most thrombi arise from cerebral arteries
or cardiogenic sources [18, 22].
1.1.3 Stroke pathophysiology
In all types of stroke, impaired blood supply of brain tissue causes ischemia and
subsequent brain damage: the lack of oxygen and glucose leads to a failure of
adenine triphosphate (ATP) production, which then leads to cell injury and death.
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Neurons are most susceptible to hypoxia and undergo cell death first, followed
by glial cells [15]. The ischemic region can be divided in two parts: the inner
core is completely oxygen-deprived, which causes an immediate necrosis of both
neurons and glial cells. The outer area, which is called penumbra, is defined as an
area with critical hypoperfusion. Cells in this area can possibly be revived by fast
intervention and restoration of blood flow. Salvaging the penumbra is the main
goal in stroke diagnostics and treatment [23]. An important differential diagnosis
of ischemic stroke is the much less common hemorrhagic stroke, which needs to
be ruled out prior to starting intravenous thrombolysis treatment, in order to avoid
fatal aggravation of the hemorrhage. Hemorrhagic strokes are caused by rupture
of a blood vessel, leading to brain hypoxia, parenchyma damage and increased
intracranial pressure [24].
1.1.4 The role of platelets in ischemic stroke
Even though platelets are the smallest of all blood cells and only fragments of
megakaryocytes, they play a major role in hemostasis, disorders that involve
thrombosis, and in ischemic stroke pathophysiology. Platelet production begins
with the formation of megakaryocytes and the subsequent fragmentation: In
megakaryocyte synthesis, nuclear duplication without cell division results in the
formation of giant cells. Cell organelles fuse at specific sites for later nascent
platelets within the megakaryocyte, until demarcation by invaginated plasma
membranes forms mature platelets [25].
In an intact vessel, platelet activation or coagulation does not occur. Upon
activation, platelets change their shape by expressing long dendritic extensions
that can facilitate adhesion. Platelets contain two types of granules: The
so-called dense granules contain adenosine diphosphate (ADP) and calcium,
which support platelet aggregation and platelet-surface coagulation reactions.
The a-granules contain numerous proteins such as von-Willebrand-factor and
platelet factor 4, which are synthesized in megakaryocytes [26]. Glycoprotein
Ib-V-IX, a receptor for von-Willebrand-factor that is located on the platelet
membrane and is constantly active, causes platelet attachment to exposed
perivascular von-Willebrand-factor [27]. A similar process of platelet attachment
occurs when exposed collagen from subendothelial matrix binds glycoprotein
Ia-IIa. Glycoprotein IIb-IIIa, the most abundantly expressed surface protein on
platelets, changes conformation during platelet activation in order to allow it to
bind fibrinogen, a process that mediates platelet aggregation [28].
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Various cerebrovascular and cardiovascular events can be traced back to
atherosclerosis, which may lead to plaque rupture and thrombosis [29]. Rupture
of an atheromatous plaque induces several processes such as platelet adhesion,
activation and aggregation. Platelet aggregation and formation of a blood clot
causes vessel occlusion or distal embolization, which is a critical event in the
pathophysiology of stroke, myocardial infarction and acute ischemia of extrem-
ities [30]. Since the role of platelet aggregation in those diseases has been
determined, antiplatelet drugs have emerged as a key approach in secondary
prevention of serious vascular events [31].
ASA, or acetylsalicylic acid, is the most frequently prescribed antiplatelet drug
for patients with severe atherosclerosis and risk factors for vascular events. ASA
inhibits thromboxane A2 production by inhibiting cyclooxygenase, the key enzyme
in thromboxane A2 synthesis [32].
1.1.5 Stroke symptoms
Stroke usually presents with sudden onset of symptoms caused by acute oc-
clusion of a brain vessel and subsequent brain tissue hypoxia. Symptoms vary
remarkably depending on severity and location of the vessel occlusion: possible
signs are deficiencies in consciousness, orientation, pupillary response and mo-
tor activation, ataxia, paralysis, paresthesia, loss of reflexes, neglect or dysarthria
[33].
1.1.6 Stroke diagnostics
Neuronal damage progresses with every minute of ischemia: it has been
estimated that every minute, 1.8 million neurons are lost irreversibly [34]. Thus, a
quick diagnosis and early intervention are crucial in the acute phase of stroke.
Cranial imaging is the single most important measure to quickly examine a
patient presenting with stroke symptoms. It is crucial to rule out an intracranial
hemorrhage, which cannot be distinguished from an ischemic stroke based on
clinical symptoms only, in order to proceed to lysis or recanalization treatment
as fast as possible. Both CT and MRI are used in the emergency department
for diagnosis but show significant advantages and disadvantages in acute stroke
diagnostics: CT scans are most commonly used in patients with suspected
stroke. They are fast, easily available, and less expensive than an MRI, and are
thus widely used in the acute phase of a stroke. They are also less susceptible
to motion artifacts and available for all patients. While showing high sensitivity for
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intracranial hemorrhage, the CT lacks sensitivity for detecting an acute ischemic
stroke in the first hours of onset [34]. These can be detected much better
with MRI imaging [35]. However, patients with intracorporal devices such as
pacemakers are not eligible for an MRI.
The second goal in stroke diagnostics, after ruling out intracranial hemorrhage,
is to define infarct core and penumbra in order to determine how much brain tis-
sue could be salvaged by early thrombolysis therapy or mechanical thrombec-
tomy [36]. Discriminating the penumbra requires a CT- or MR-based perfusion
imaging: in both scans, intravenous contrast medium is applied, and cerebral
blood flow and cerebral blood volume are measured. The infarct core, which con-
tains irreversibly damaged brain tissue, can be distinguished from the penumbra,
which is defined as an area without perfusion, but with remaining diffusion, which
suggests viable brain tissue that could regain normal function when blood flow is
restored rapidly enough [37].
Figure 1: Evolution of penumbra and infarct core
When blood flow to a brain area is impaired, the infarct core defines the area of
irreversible neuron damage. The surrounding area, the so-called penumbra,
includes viable brain tissue in an area with no perfusion, in which neurons
could possibly be salvaged by restoration of blood flow. Without treatment,
neurons in the penumbra undergo apoptosis and the infarct core takes over
the penumbra area over the course of weeks. Figure adapted from Dirnagl et
al., 1999 [38].
1.1.7 Stroke therapy
Early intervention such as reopening of the artery and restoration of blood flow
can salvage ischemic brain tissue and limit infarct consequences. Time passed
before achieving recanalization, size of the ischemic area and collaterals are ma-
jor determinants for outcome and life expectancy. Nowadays, the most commonly
used treatment option is intravenous tissue plasminogen activator (tPA), which
causes rapid intraarterial thrombus dissolution. It has been shown that patients
who receive tPA treatment are 30% more likely to have minimal or no residual
disabilities after 3 months compared to placebo controls [39]. The time frame for
tPA administration is considered 4.5h after symptom onset [40], however, recent
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studies revealed that patients who show salvageable brain tissue in perfusion
imaging benefit from thrombolysis therapy up to 9 hours after symptom onset
[41]. Patients with unknown onset of symptoms (e.g. wake-up stroke) have
been shown to benefit from thrombolysis beyond the 4.5-hour time frame, if
a mismatch between diffusion-weighted imaging and FLAIR (fluid-attenuated
inversion recovery) sequence can be detected [42].
In addition to intravenous thrombolysis, endovascular recanalization has
emerged as an important treatment option for ischemic stroke patients with an
occlusion of a brain vessel in the proximal anterior circulation within the first 6
hours after symptom onset [43]. A recent study showed that patients might even
benefit from mechanical thrombectomy up to 24 hours after symptom onset, if
they present with an infarct volume and clinical symptom severity mismatch [44].
1.2 Transient ischemic attack (TIA)
A transient ischemic attack (TIA) is characterized by sudden onset of neurologi-
cal symptoms that completely resolve without intervention. According to the WHO
criteria proposed in 1988, a TIA used to be defined as symptoms resolving in <
24 hours [45], under the assumption that no permanent brain damage occurs in
a TIA. However, since the introduction of more accurate diagnostic means such
as high-resolution diffusion-weighted imaging (DWI), it has been suggested that
a considerable number of TIA patients do, in fact, show signs of permanent tissue
damage in brain imaging [46]. This led to a redefinition of a TIA that is inde-
pendent of time: ’A transient episode of neurological dysfunction caused by focal
brain, spinal cord, or retinal ischemia, without acute infarction’ [47]. There are
current attempts to further redefine TIA and stroke, since it has recently been
shown that the majority of TIA patients show evidence of brain injury [48]. A
TIA is the most important risk factor for an ischemic stroke, the risk for which
is estimated to be 12-20% in the first three months after a TIA or a minor stroke
[49]. Diagnostic measures, primary and secondary prevention for ischemic stroke
equally apply for TIA patients. Even though 10% of minor stroke and TIA patients
show an intracranial occlusion in neurovascular imaging [50] thrombolysis treat-
ment is not eligible for those patients [51]. Among patients with acute deficits that
show no signs of tissue infarction upon admission, a biomarker that could distin-
guish those patients from both ischemic stroke patients and patients with other
neurological pathologies would a remarkable improvement in diagnostic accuracy
and efficiency in emergency treatment compared to neuroimaging, as well as in
choosing the best treatment option for the patient.
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1.3 Stroke biomarkers
Currently, cranial imaging is the most useful diagnostic measure to assess stroke
patients with acute neurological symptoms. It can rule out other pathologies that
present with similar symptoms and determine the treatment course upon hospital
arrival. However, the disadvantages of CT and MRI have led to the desire of
finding a biomarker that could support imaging in acute stroke diagnostics. An ex-
ample of successful usage of blood-based biomarkers in the clinical emergency
setting can be observed in the identification of cardiac isoenzymes troponin I and
T, which has revolutionized diagnostics of acute myocardial infarction [52].
A diagnostic biomarker for ischemic stroke requires high sensitivity and
should have high specificity in order to distinguish ischemic stroke patients from
healthy controls, patients with a TIA or hemorrhagic stroke as well as from
patients with stroke mimics such as seizures, migraine or cerebral infections.
Ideally, it should also be able to distinguish stroke patients from other ischemic
pathologies such as myocardial infarctions or pulmonary embolisms. However, a
diagnostic biomarker could lack specificity and still be useful in the clinical setting
by ruling out a disease (such as D-Dimer test in pulmonary embolism) [53],
or support diagnosis in diseases with similar pathophysiological processes but
entirely different clinical presentation, such as myocardial and cerebral infarctions.
Difficulties in the search for blood-based biomarkers for stroke include delayed
rise of plasma levels of brain-derived biomarkers in the blood stream due to
the blood-brain barrier. Some potential biomarkers show correlation to infarct
size, however, even a small infarction in an important area of the brain, such as
Broca’s area, could cause remarkable disability that cannot be quantified by a
biomarker [54].
Also, techniques to quickly and accurately measure levels of the biomarker
need to be widely available. So far, multiple studies have tried to identify blood- or
cerebrospinal fluid (CSF)-based biomarkers, but none of them fulfilled all of these
requirements [55].
1.3.1 Neuronal and glial markers
S-100-B (S100B) is a calcium-binding peptide, which is secreted by astrocytes
after brain injury or neurodegenerative processes and has been suggested to
exert neuroprotective actions [56]. Increased serum levels have been observed
after ischemic stroke, but also after brain trauma or in the setting of Alzheimer’s
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disease or psychiatric diseases [57]. S100B levels have been shown to correlate
with infarction size and to be associated with higher risk for hemorrhagic trans-
formation [58].
Glial fibrillary acidic protein (GFAP) is an intermediate filament protein, which
is part of the cytoskeleton of astrocytes and ependymal cells. Increased serum
levels are specific for cerebral injury [59]. GFAP has been shown to be more
sensitive than S100B, particularly in smaller lesions and minor strokes. However,
both S100B and GFAP show delayed rise and peaks of serum concentration lev-
els after ischemic stroke, which limits their usefulness as a diagnostic biomarker
in the acute phase [60, 61].
Increased neuron-specific enolase (NSE) levels in the CSF occur after
ischemic stroke, but also after traumatic brain injuries or intracerebral bleeds
[62]. Levels peak at 4-8 hours after symptom onset, but serum and CSF levels
differ widely and do not seem to show a consistent change after ischemic stroke
[63].
Neurofilaments are part of the structural scaffold of neurons. They consist
of three subunits, with the neurofilament light protein (NfL) being the core of the
filament. A recent study of our group showed that ischemic stroke patients have
higher serum NfL levels on the day of stroke onset compared to a healthy control
group, with a peak at 7 days. Furthermore, NfL levels were shown to correlate with
infarct volumes, and to predict clinical outcome [64]. However, diagnostic utility in
the setting of an acute stroke was inferior to miR-125a-5p, miR-125b-5p and miR-
143-3p that we previously identified as biomarkers of acute ischemic stroke [65].
Also, elevated NfL serum levels in a patient with suspected acute ischemic stroke
could possibly be caused by previous minor ischemic events weeks or months
prior to current symptom onset, since it has been shown that serum NfL levels
remain elevated for months after a stroke event [64].
1.3.2 Coagulation markers
Since thrombus formation is an essential part in ischemic stroke pathophys-
iology, coagulation markers might show potential as diagnostic biomarkers:
Thrombomodulin is a protein that is present in the endothelial membrane. It
binds thrombin and activates protein C and is therefore part of an important
antithrombotic mechanism in the physiological state. Protein expression in the
brain is controlled by astrocytes [66]. Some types of thrombomodulin have been
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shown to be associated with cardiovascular events, but not with stroke events
[67], and do not show significant changes in stroke patients compared to control
groups [68].
Since other unspecific coagulation markers such as D-Dimers have been
shown to be very useful as diagnostic biomarkers in other diseases [53], recent
studies addressed other coagulation markers that could possibly be associated
with ischemic stroke:
Increased fibrinogen levels after ischemic stroke have been shown to cor-
relate with infarction size and outcome [69, 70]. Also, fibrinopeptide A, b-
thromboglobulin, prothrombin fragments 1 and 2, thrombin-anti-thrombin com-
plexes, platelet factor 4 and von-Willebrand-factor plasma levels have been shown
to be associated with stroke severity [71, 72]. D-Dimers have been shown to be
acutely elevated in ischemic stroke [73], but are not sensitive enough to serve as
a diagnostic biomarker for ischemic stroke [74].
1.3.3 Inflammatory markers
After stroke, a local immune response is always present in the ischemic area
of the brain: Cytokines are released in order to mediate inflammatory and
immune responses [75]. Neuronal and glial cells actively and passively secrete
interleukins, transforming growth factor beta (TGF-b), intercellular adhesion
molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), selectins or
tumor-necrose factor alpha (TNFa) into the blood stream [76]. C-reactive protein
(CRP) is produced in the liver in response to interleukin-6 (IL-6) activation and
has a crucial role in inflammatory processes [77]. Since atherosclerosis occurs
based on inflammatory reactions in the endothelium, increased CRP levels have
been shown to be associated with higher risk for stroke [78], infarct volume,
stroke severity, clinical outcome [79], and risk for recurrent stroke [80]. However,
none of those markers of systemic or local immune response have proven to
have neither the sensitivity nor specificity that a diagnostic biomarker for ischemic
stroke requires.
So far, most serum-based biomarkers showed poor results in prospective test-
ing in acute diagnosis of ischemic stroke overall [60], mostly because their dis-
tribution patterns overlap considerably in patient and healthy control groups. An-
other difficulty is that different population groups may show different distribution
and cut-off levels [81, 82]. Also, many biomarkers show a delayed peak days after
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the initial event, which excludes them from being useful in an emergency depart-
ment setting [60, 62]. In most cases, other neurologic diseases such as migraine,
seizures, infections and dementia can present as stroke mimics and cause alter-
ations in biomarker levels as well [83]. So far, none of the studies investigating
biomarkers has shown results, which would be promising to facilitate ischemic
stroke diagnostics or replace cranial imaging in ischemic stroke diagnostics in the
near future.
1.4 MicroRNAs
’microRNAs (miRNAs) are endogenous, ⇠22 nucleotide RNAs that can play im-
portant roles in animals and plants by targeting mRNAs for cleavage or transla-
tional repression’ [84]. They were first discovered in 1993 [85]. Ever since their
discovery, knowledge about their biogenesis and functions has grown due to their
potential for diagnostic and therapeutic use. Nowadays, there are more than 2500
different miRNAs identified in humans, with numbers constantly increasing [86].
1.4.1 Biosynthesis
miRNA genes are widely spread over the entire genome. One gene can either
encode for a single miRNA hairpin precursor or for multiple precursors. The pri-
mary miRNAs (pri-miRNAs) ’act as substrates for two members of the RNase III
family of enzymes, Drosha and Dicer. The product of Drosha cleavage, an ⇠70
nucleotide pre-miRNA [(precursor miRNA)] , is exported to the cytoplasm where
Dicer processes it to an ⇠20 base pair miRNA/miRNA* duplex’ [87]. The strands
are named 5p and 3p. The mature single strands then join the RNA-induced si-
lencing complex (RISC), which can now bind the 3’-untranslated region (3’-UTR)
of mRNAs with their 5’-untranslated region (5’-UTR) [87].
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Figure 2: miRNA biogenesis and mechanisms of action
Transcription of miRNAs as described above. In most cases, only one of the
strands is incorporated into the RNA-induced silencing complex (RISC). The
RISC complex can recognize target regions on messenger RNAs (mRNAs).
Figure from van Rooij, Olson 2012 [88]. Permission granted by Springer Na-
ture.
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Figure 3: Biogenesis of miRNAs
Two miRNAs derive from the same precursor, the so-called pre-miRNA. Since
both resulting miRNAs are only partially complementary, they can possess
remarkably different functions and be involved in different pathways. Figure
modified from Schober et. al., 2014 [89].
1.4.2 Functions
The RISC can downregulate gene expression by post-transcriptional regulation
of messenger RNAs (mRNAs): if the mRNA has sufficient complementarity to the
miRNA incorporated in the RISC, the target mRNA can be cleaved by the com-
plex. In case of a short area of mRNA-miRNA complementarity, the RISC can
bind the 3’-UTR of the target mRNA, thereby repressing translation [84]. Usually,
the miRNA-mRNA complementary base-pairing is only 6-8 base pairs, which al-
lows the miRNA to bind different mRNAs [87]. Even though the exact regulatory
mechanisms are still unknown, many miRNAs have been shown to be involved in
neuronal gene expression [90], brain morphogenesis [91] and stem cell division
[92].
1.4.3 Circulating miRNAs
Beyond their intracellular function, some miRNAs are present in blood plasma.
They ’are remarkably stable in plasma and serum, and resistant to RNase
activity, as well as extreme pH and multiple numbers of freeze-thaw cycles’
[93]. While endogenous miRNAs remain stable under experimental conditions,
synthetic miRNAs that are added to plasma are quickly degraded by RNAses
[94], suggesting a protective mechanism to prevent degradation of endogenous
miRNAs. ’miRNAs are carried by encapsulation in membrane-derived vesicles
such as exosomes, microvesicles, apoptotic bodies, RNA-binding proteins such
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as Argonaute 2, or lipoprotein complexes such as HDL’ [95].
reduThe discovery of miRNAs that are present in microparticles has also raised
the question as to whether miRNAs are actively secreted by a cell, taken up
by a different target cell, potentially regulating its gene expression and thus
participating in cell-to cell communication [96, 97].
The remarkable stability of circulating miRNAs, their characteristic expression
patterns in different tissue or cell types, and the fact that miRNA levels can eas-
ily be detected and quantified with high sensitivity and specificity by real-time
polymerase chain reaction (PCR) and microarrays [98] has led to the initiation of
multiple studies that focus on their use as biomarkers in diagnostics or predicting
outcome, for example in cardiovascular diseases or diabetes mellitus [99]. For
example, four cardiac miRNAs (miR-1, miR-133, miR-208a and miR-499) have
been found to show an elevation in plasma levels of patients in the acute phase
of myocardial infarction [100, 101].
Figure 4: Biogenesis of miRNAs and functions of long non-coding RNAs
A: miRNA biogenesis in nucleus and cytoplasm. Mature miRNAs are trans-
ported by vesicles or proteins, which prevent them from degradation. B: Func-
tions of long non-coding RNAs. Image by Dr. Johannes Richers. AGO =
Argonaute protein; pre-miRNA = precursor microRNA; pri-miRNA = primary
microRNA; RISC = RNA-induced silencing complex. Figure from Tiedt, Dich-
gans 2018 [102]. Permission granted by Wolters Kluwer Health, Inc.
1.4.4 Platelet-associated miRNAs
Platelet aggregation is an essential pathophysiological process in both embolic
and thrombotic ischemic stroke. Upon activation, platelets release microparticles
that contain proteins and inflammatory mediators, but also circulating miRNAs
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that use microparticles as a protective medium and as a transport vehicle in
plasma [103]. It is assumed that platelets inherit their miRNA content from
megakaryocytes [104], and for many circulating miRNAs, platelets have been
identified as a major cellular source [105]. It has been discovered that megakary-
ocytes strongly contribute to circulating miR-126 levels [106], a well-studied
miRNA that has been reported to be specifically expressed in endothelial cells
when first identified [107].
Up to now, about 750 miRNAs have been identified as being associated with
platelets [108]. Platelet miRNA plasma levels in healthy individuals remain stable
over the lifespan of a platelet [109]. ’In response to antiplatelet drugs, circulating
levels of many miRNAs are reduced in platelet-poor plasma (PPP)’ [108]. Lev-
els can also be altered in various diseases, such as myocardial infarction [110],
diabetes mellitus [111], and cancer [112].
Figure 5: Non-coding RNAs regulating atherogenesis
Association of long non-coding RNAs and miRNAs to different stages of
atherosclerosis. Image by Dr. Johannes Richers. SMC = smooth muscle
cell. Figure from Tiedt, Dichgans 2018 [102]. Permission granted by Wolters
Kluwer Health, Inc.
1.5 Prior research in our group
Our group has been interested in identifying miRNAs that show altered expres-
sion patterns in acute ischemic stroke patients. By RNA sequencing, we identified
differentially expressed circulating small, non-coding RNAs in the acute phase of
ischemic stroke and identified, validated and replicated three miRNAs, that were
upregulated in the acute phase of ischemic stroke and transient ischemic attack
patients compared to healthy controls: miR-125a-5p, miR-125b-5p and miR-143-
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3p [65]. A random forest classification showed an area under the curve (AUC) of
0.90 for the combination of all three miRNAs, which was superior to cranial CT
and previously reported biomarkers such as NSE or IL-6. Longitudinal analysis
of circulating levels of those three miRNAs up to 90 days after stroke showed
normalization in expression levels of miR-125b-5p and miR-143-3p on day 2 af-
ter stroke, while miRNA-125a-5p levels remained elevated over the course of 90
days. ’Levels of miR-125a-5p, miR-125b-5p, and miR-143-3p were not affected
by chemical hypoxia of Neuro2a cells in vitro and in 2 different experimental stroke
models’ [65]. ’All 3 microRNAs depended on platelet numbers in a platelet spike-
in experiment’ [65].
15
2 OBJECTIVES AND GOAL OF THE DISSERTATION
2 Objectives and Goal of the Dissertation
Since stroke is one of the leading causes of death and disability worldwide,
requires fast diagnosis and treatment in order to minimize permanent brain
damage and disability, a fast, widely available diagnostic tool with both high
sensitivity and specificity would be of vital importance. As reviewed before, no
diagnostic measure that meets all of these criteria has been identified yet. So far,
neuroimaging is the best and most accurate way to diagnose a stroke. CT scans
can rule out intracranial hemorrhage with high sensitivity, but lack sensitivity in
distinguishing ischemic stroke from stroke mimics such as seizures, migraines or
cerebral infections early after symptom onset. MRI imaging has high sensitivity
in the early stages of stroke but is often considered to be too time-consuming to
be used in a critical clinical situation.
An ideal biomarker for ischemic stroke should have high sensitivity as well
as high specificity, in order to quickly diagnose an ischemic stroke and to rule
out a TIA or a stroke mimic. A blood-based biomarker should present with rising
plasma levels in the early hours after symptom onset and make it possible to
distinguish ischemic stroke patients from healthy people and from people with
other pathologies. It should be cost-efficient, easily and quickly measurable in the
emergency department setting, as well as valid and reliable. So far, all previously
suggested blood-based biomarkers such as NSE, GFAP or S100B have failed to
meet those criteria. miRNAs circulate in the blood with high stability and show
tissue-specific expression patterns, thus showing potential as biomarkers for
disease states. Since platelet function, activation and aggregation is a major part
of ischemic stroke pathophysiology, we here investigated the diagnostic value of
platelet-associated miRNAs.
The goal of this project is 1) to identify miRNAs that show differential plasma
levels in ischemic stroke patients compared to TIA patients and healthy subjects
2) to assess the diagnostic value of these miRNAs in a clinical setting and 3)
to analyze miRNA levels in murine stroke in a first step towards investigating
molecular mechanisms of miRNA production, release, circulation and regulation
in ischemic stroke pathophysiology.
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3 Materials and Methods
3.1 Materials
3.1.1 Equipment
-20°C Freezer Co. Liebherr (Bulle, CH)
-80°C Freezer Co. Thermo Fisher (Waltham, MA, USA)
4°C Freezer Co. Siemens (Munich, D)
Accu-jet Pipette Controller Co. BrandTech (Essex, CT, USA)
autoMACS Pro Cell Separator Co. Miltenyi Biotec (Bergisch-Gladbach, D)
Centrifuge 5427 R Co. Eppendorf (Hamburg, D)
Centrifuge 5810 R Co. Eppendorf (Hamburg, D)
Centrifuge Heraeus Megafuge 16 Co. Thermo Fisher (Waltham, MA, USA)
Centrifuge Peqlab Perfect Spin 24 R Co. VWR Intern. (Center Valley, PA, USA)
Confocal Microscope Sp5 Co. Leica (Wetzlar, D)
CryoStat NX70 Co. Thermo Fisher (Waltham, MA, USA)
Gilson Pipettes (10µl, 20µl, 200µl, 1000µl) Co. Thermo Fisher (Waltham, MA, USA)
Heater Thermocenter Co. SalvisLab (Rotkreuz, CH)
Hellendahl Glass Box Co. Thermo Fisher (Waltham, MA, USA)
Ice Machine Co. Ziegra (Isernhagen, D)
Microscale Balance Co. Acculab (Central Islip, NY, USA)
Microtome CryoStat NX70 Co. Thermo Fisher (Waltham, MA, USA)
Millipore Water Suspenser Co. Merck (Darmstadt, D)
Multi-Channel Pipet 10µl, 100µl Co. Eppendorf (Hamburg, D)
Multipette Co. Eppendorf (Hamburg, D)
Nitrogen Cryo Tank Co. Cryo Anlagenbau (Wilnsdorf, D)
Pap Pen Co. Kisker Biotech (Steinfurt, D)
pH-Meter Co. SI Analytics (Rye Brook, NY, USA)
Precision Balance Co. Acculab (Central Islip, NY, USA)
Roche LightCycler 480/II Co. Roche (Basel, CH)
ThermoMixer Pro Co. CellMedia (Elsteraue, D)
Veriti Thermal Cycler Co. Thermo Fisher (Waltham, MA, USA)
Vortex Shaker Peqlab Co. VWR Intern. (Center Valley, PA, USA)
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3.1.2 Consumables
396-well Light Cycler qPCR Plate Co. Roche (Basel, CH)
96-well MicroPlate Co. Sigma-Aldrich (St. Louis, MO, USA)
Butterfly Venofix Co. Braun (Melsungen, D)
Combitips 2ml, 5ml Co. Eppendorf (Hamburg, D)
Costar Stripettes 5ml, 10ml, 20ml Co. Sigma-Aldrich (St. Louis, MO, USA)
DNA LoBind Tubes 0.5ml Co. Eppendorf (Hamburg, D)
DNA LoBind Tubes 5ml Co. Eppendorf (Hamburg, D)
EDTA 9ml Monovette Co. Sarstedt (Hildesheim, D)
FACS Polystyrene Test Tubes Co. Elkay (Basingstoke, UK)
Falcon 50ml Tubes Co. Thermo Fisher (Waltham, MA, USA)
Filter Tips 10µl, 20µl, 200µl, 1250µl Co. VWR Intern. (Center Valley, PA, USA)
Fluoromount Mounting Medium Co. Sigma-Aldrich (St. Louis, MO, USA)
Gloves Vasco Powder-Free Co. Braun (Melsungen, D)
Kimwipes KimTech Co. Thermo Fisher (Waltham, MA, USA)
Menzel Cover Glasses 24x60mm Co. VWR Intern. (Center Valley, PA, USA)
Microvette 300µl Co. Sarstedt (Hildesheim, D)
Parafilm Co. Sigma-Aldrich (St. Louis, MO, USA)
Pipet Tips TipOne Co. Starlab (Hamburg, D)
RNAse Away Spray Co. Thermo Fisher (Waltham, MA, USA)
Sealing foil 386-well Plate Co. Roche (Basel, CH)
Sealing foil 96-well Plate Co. Sigma-Aldrich (St. Louis, MO, USA)
Superfrost Plus Slides Co. Thermo Fisher (Waltham, MA, USA)
Tissue Tek O.C.T. Compound Co. Scigen (Gardena, CA, USA)
VWR Reagent Reservoir Co. VWR Intern. (Center Valley, PA, USA)
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3.1.3 Chemicals
0,5M EDTA, pH 8.0 Co. Invitrogen (Carlsbad, CA, USA)
1-Methylimidazole Co. Sigma-Aldrich (St. Louis, MO, USA)
12M HCl Co. Carl Roth (Karlsruhe, D)
Bovine serum albumin (BSA) Co. Sigma-Aldrich (St. Louis, MO, USA)
Citric Acid Co. Sigma-Aldrich (St. Louis, MO, USA)
Deionized formamide Co. Life Technologies (Carlsbad, CA, USA)
Dextran sulfate Co. Sigma-Aldrich (St. Louis, MO, USA)
EDC(N-(3-Dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride)
Co. Sigma-Aldrich (St. Louis, MO, USA)
Ethanol Absolute for Analysis Co. Sigma-Aldrich (St. Louis, MO, USA)
Ficoll 400 PM Co. Sigma-Aldrich (St. Louis, MO, USA)
Glycine Co. Sigma-Aldrich (St. Louis, MO, USA)
Glycogen Ambion Co. Thermo Fisher (Waltham, MA, USA)
HISTOPAQUES 1077 Co. Sigma-Aldrich (St. Louis, MO, USA)
Isopropanol Co. Sigma-Aldrich (St. Louis, MO, USA)
MACS Running Buffer Co. Miltenyi-Biotec (Bergisch-Gladbach, D)
MACS Washing Buffer Co. Miltenyi-Biotec (Bergisch-Gladbach, D)
NaCl Co. Carl Roth (Karlsruhe, D)
Normal goat serum (NGS) Co. Sigma-Aldrich (St. Louis, MO, USA)
Nuclease-free water Co. Qiagen (Venlo, N)
Polyvinylpyrrolidone Co. Sigma-Aldrich (St. Louis, MO, USA)
Potassium dihydrogen phosphate Co. Sigma-Aldrich (St. Louis, MO, USA)
Rotihistol (Xylene) Co. Carl Roth (Karlsruhe, D)
Salmon sperm DNA Co. Applichem (Gatersleben, D)
Sodium Chloride Co. Sigma-Aldrich (St. Louis, MO, USA)
Sodium Citrate Co. Sigma-Aldrich (St. Louis, MO, USA)
Sodium phosphate dibasic dihydrate Co. Sigma-Aldrich (St. Louis, MO, USA)
TRIS Co. Sigma-Aldrich (St. Louis, MO, USA)
Tween 20% Co. Carl Roth (Karlsruhe, D)
UltraPure 10% SDS solution Co. Invitrogen (Carlsbad, CA, USA)
UltraPure 20x saline sodium citrate (SSC) Co. Invitrogen (Carlsbad, CA, USA)
Yeast tRNA Co. Invitrogen (Carlsbad, CA, USA)
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3.1.4 Buffers and solutions
Platelet spike-in experiment





Fluorescent in-situ hybridization (FISH)
DEPC-H2O 1ml Diethylpyrocarbonate (DEPC)
1l Millipore Water (0,1% v/v)
70% Ethanol 700ml 100% Ethanol
300ml DEPC-H2O
50% Ethanol 500ml 100% Ethanol
500ml DEPC-H2O
NaCl (3M) 87.66g NaCl
500ml DEPC-H2O
Tris-HCl (1M, pH 7.4/8.0) 121.1g Tris base
800ml DEPC-H2O
Adjust to pH 7.4 or 8.0 by adding 12M HCl
Fill up to 1l with DEPC-H2O
10x TBS (Tris-buffered saline) 500ml 1M Tris-HCl pH 7.4
90g NaCl
410ml DEPC-H2O
Sodium Citrate 0.1M 29.41g Sodium citrate
1l DEPC-H2O
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50x Denhardt’s solution 1g Ficoll 400
150ml DEPC-H2O
1g BSA (bovine serum albumin)
1g Polyvinylpyrrolidone
Hybridization buffer 1ml Tris-HCl pH 8.0
50ml deionized formamide
2.5ml 10% SDS
20mg yeast tRNA (final concentration
500µg/ml)
2ml 50x Denhardt’s solution (final concen-
tration 1x)
20ml 3M NaCl (final concentration 600mM)
2.5ml 0.5M EDTA
10g Dextrane sulfate (final concentration
10%)
100ml DEPC-H2O
Diluted SSC 1x: 50ml 20x SSC + 95ml DEPC-H2O
2x: 10ml 20x SSC + 90ml DEPC-H2O
0.2x: 1ml 20x SSC + 99ml DEPC-H2O
Citric Acid 0.1M 9.56g Citric acid
500ml DEPC-H2O
Methylimidazole buffer 1.6ml 1-Methylimidazole
130ml DEPC-H2O
Adjust to pH 8.0 with 12M HCl
16ml NaCl 3M
12ml DEPC-H2O
EDC solution 10ml Methylimidazole buffer
307mg EDC
Blocking buffer 0.1g BSA (bovine serum albumin)
5ml PBS
0.3g NGS (normal goat serum)
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10x PBS 800g NaCl
20g KCl
144g Na2HPO42- + 2H2O
24g KH2PO4
3.1.5 Primers, probes and kits
Platelet spike-in experiment
CD61 MicroBeads human Co. Miltenyi Biotec (Bergisch-Gladbach, D)
RNA isolation
miRCURY RNA-Isolation Kit for Biofluids Co. Exiqon (Vedbaek, DK)
RNA Spike-in Kit, Uni-RT Co. Exiqon (Vedbaek, DK)
cDNA synthesis
Universal cDNA Synthesis Kit II Co. Exiqon (Vedbaek, DK)
Uni-Sp6 LNA PCR Primer Set Co. Exiqon (Vedbaek, DK)
RT-qPCR (reverse transcription quantitative polymerase chain reaction)
Exilent SYBR Green Master Mix Co. Exiqon (Vedbaek, DK)
Fluorescent in-situ hybridization (FISH)
FISH LNA probes, 5’- and 3’ DIG-labeled Co. Exiqon (Vedbaek, DK)
FISH Scramble probes, 5’- and 3’ DIG-
labeled
Co. Exiqon (Vedbaek, DK)
a-NeuN mouse Co. Abcam (Cambridge, UK)
a-GFAP mouse Co. Abcam (Cambridge, UK)
a-digoxigenin POD Co. Sigma-Aldrich (St. Louis, MO, USA)
Anti-mouse Alexa Flour 488 Co. Abcam (Cambridge, UK)
Cy3 TSA Co. Perkin Elmer (Waltham, MA, USA)
DAPI Co. Thermo Fisher (Waltham, MA, USA)
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3.1.6 miRNAs















Table 1: Sequences of miRNAs used in the experiments
3.2 Methods
3.2.1 Patient recruitment and study population
During a three-year period from 2014 to 2017, ischemic stroke patients and
transient ischemic attack patients were recruited through the emergency depart-
ment at the Klinikum der Universität München, the university hospital at Ludwig-
Maximilians-Universität, Munich. Healthy control subjects were recruited through
the outpatient clinic of the Institute for Stroke and Dementia Research, and were
matched for age, sex and vascular risk factors. We included patients over the
age of 18, with less than 24 hours between symptom onset and blood draw upon
hospital arrival. Only patients who later had a final diagnosis of ischemic stroke,
which was defined by an acute focal neurologic deficit as well as evidence for
stroke on neuroimaging (positive lesion in diffusion-weighted imaging on MRI, or
a new lesion on a delayed CT scan), were included in the stroke group. For the
derivation sample, we excluded patients with active malignant, inflammatory or in-
fectious diseases or surgery within the last month. We also excluded patients who
were treated with low-molecular or unfractionated heparin, patients with intake of
antiplatelet medication within the last month, recent cardiovascular events such
as myocardial infarction, stroke or TIA, or signs for a silent central nervous system
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(CNS) infarction on neuroimaging. For the replication sample, we only excluded
patients with heparin treatment within the last month and patients with myelo-
proliferative disorders such as polycythemia vera or essential thrombocythemia.
For TIA patients in the replication sample, a TIA was defined as acute neurologic
symptoms lasting less than 24h, without evidence for brain ischemia in MRI or
CT imaging. Blood of all ischemic stroke and TIA patients was drawn as soon as
possible after hospital arrival and processed as described below. Beyond collec-
tion upon hospital arrival, blood samples were also collected on days 2, 3, 7 (or
the day of discharge), and 90. Informed and written consent was obtained from
all subjects included. The study was approved by the local ethics committee and
conducted according to the Declaration of Helsinki.
3.2.2 Blood sampling and processing
Blood was drawn into a 9ml EDTA-tube using 21-gauge needles and incubated at
room temperature for 30 minutes. The samples were centrifuged for 10 minutes
at 2000g, followed by 15 minutes at 2500g. The samples were kept at -80°C.
3.2.3 Platelet spike-in experiment
This experiment was adapted from a protocol published by Kaudewitz et al [113].
Blood from 4 healthy volunteers was drawn into a 9ml EDTA-tube and incubated
at room temperature for 30 minutes. To eliminate erythrocytes, the samples were
’centrifuged at 190g for 30 minutes. All centrifugations were performed at room
temperature without brake’ [113]. The supernatant was transferred into a different
5ml Falcon tube and centrifuged at 280g for 10 minutes at room temperature with-
out brakes, in order to pellet white blood cells. The supernatant was again trans-
ferred into another Falcon tube, and the plasma was mixed by pipetting up and
down several times to assure that remaining cells were spread equally through-
out the plasma sample. The volume of this plasma sample (so-called platelet-rich
plasma, PRP) was quantified, and 200µl of this PRP were transferred into a sep-
arate Falcon tube and stored on ice. The remaining PRP was pipetted back onto
the cell pellet, to ensure that platelets that may already be pelleted remain in the
sample. The sample was centrifuged at 1180g for 10 minutes under the same
conditions as previously described, pelleting the platelets. ’The resulting super-
natant was PPP’ [113]. PPP was transferred into a different Falcon tube, and
200µl of PPP were stored on ice. The remaining pellet, which contained platelets
and white blood cells, was dissolved in phosphate-buffered saline (PBS). The so-
lution was transferred into a glass FACS tube and centrifuged at 1500g for 10
minutes at 15°C, now using slow brakes. The supernatant was discarded. In
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order to ensure that the plasma sample contained no cells other than platelets
a magnetic activated cell sorting (MACS) cell separation was performed as de-
scribed below. ’The final platelet pellet was resuspended in 1/20 of the volume
of original PRP to obtain a 20x stock platelet solution. The 20x platelet solution
was then spiked back into the PPP from the same donor to achieve 200%, 100%,
50% and 5% spike-ins’ [113]. miRNA expression levels in the different samples
were analyzed via RNA-isolation, complementary DNA (cDNA) synthesis, and
RT-qPCR as described above. In order to quantify platelet contribution to plasma
expression levels of a miRNA, each threshold cycle value (Ct-value) of the spike-
in samples (5%, 50%, 100%, 200%) was divided by the PRP value, and the 100%
sample was compared to the PRP sample serving as an intrinsic control of the
experiment.
5% 199.5µl PPP + 0.5µl of pellet
50% 195µl PPP + 5µl of pellet
100% 190µl PPP + 10µl of pellet
200% 180µl PPP + 20µl of pellet
Table 2: Spike-in of platelets in platelet-poor plasma
Spike-in of various amounts of platelets into PPP.
Figure 6: Platelet spike-in experiment
Analysis of platelet contribution to circulating miRNA plasma levels. MACS =
magnetic activated cell sorting. PRP = platelet-rich plasma. PPP = platelet-
poor plasma.
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3.2.4 MACS cell separation
3ml of MACS running buffer were added to the cell pellet obtained in the platelet
spike-in experiment. The sample was centrifuged at 1500g for 10 minutes at
15°C with slow brakes. The cell pellet was resuspended in 80µl of MACS running
buffer, and 10µl of Miltenyi Biotec CD61 MicroBeads for human samples were
added. The solution was mixed by pipetting up and down several times, and then
incubated for 30 minutes at 4°C, allowing the MicroBeads to attach to the CD61
receptor, which is ubiquitously expressed on platelets. After 30 minutes, the cells
were suspended in 2ml of MACS running buffer and centrifuged at 1500g for 10
minutes at 15°C once again, the supernatant was discarded. The MicroBead-
labeled cells were dissolved in 300µl of MACS running buffer and added onto a
5ml tube rack. Two more glass tubes per sample were added for the positively
and negatively selected cells. The automatic program ’Possel + Qrinse’ was used,
which performed a positive selection of magnetically labeled CD61-positive cells
and a quick washing step between samples. The positively selected platelets
were once more centrifuged at 1800g for 10 minutes at room temperature without
brakes.
3.2.5 Animal experiments
Animal experiments were performed with the kind help of Uta Mamrak (AG
Plesnila, ISD), Gemma Llovera Garcia and Vikramjeet Singh (AG Liesz, ISD).
We used wild-type C57BL/6 mice from Charles River laboratories. Experimental
stroke models were conducted as previously described [65]. In short, mice were
randomly assigned to either the experimental stroke group or the control sham
group. All mice were anesthetized using isoflurane with a mixture of 30% O2 and
70% N2O.
In the photothrombosis model, animals received 10µl/g body weight of 1%
Rose Bengal in PBS intraperitoneally, and the brain was then locally illuminated
by a fiber optic laser in order to induce a thrombotic stroke. In the distal middle
cerebral artery occlusion (dMCAo) model, the middle cerebral artery (MCA) was
permanently occluded by high-frequency electrocoagulation.
Blood sampling and processing were performed by a blinded experimenter.
For final blood collection, mice were anesthetized using ketamine (120mg/kg)
and xylazine (16mg/kg). Blood was collected by puncturing the right ventricle
using 25-gauge needles. Blood was immediately drawn into EDTA-tubes.
Samples were incubated for 30 minutes at room temperature, then centrifuged at
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2000g for 10 minutes and for 2500g for 15 minutes at 15°C. Samples were kept
at -80°C. A perfusion with 20ml of saline was performed with the mice used for
fluorescent in-situ hybridization. The brain was extracted, frozen in an isopentane
solution for 10 minutes and then stored at -80°C until further processing [114].
All experiments were approved by the governmental committee of upper
Bavaria and conducted according to the guidelines for the use of experimental
animals.
3.2.6 RNA isolation and cDNA synthesis
miRNA was isolated using the miRCURY RNA-Isolation Kit for Biofluids (Exiqon,
Vedbaek, Denmark). RNA was extracted from 200µl per human plasma sample
and 100µl per mouse sample. Following the manufacturer’s recommendation,
we added 60µl lysis buffer, 1.25µl glycogen to increase nucleic acid recovery
[115] and Spike-ins (Exiqon Spike-ins UniSp2, 4 and 5) to each sample. 20µl of
precipitation buffer provided in the kit was added. The last lysis step included
a treatment with 270µl of isopropanol. Plasma was transferred onto provided
filtered columns, followed by two washing steps with washing solutions I and II.
Plasma samples were treated with 50µl DNAse provided in the kit and incubated
for 15 minutes, followed by three identical washing steps. The remaining RNA
on the column was diluted in 50µl of nuclease-free water, and either stored
at -80°C or immediately processed for cDNA synthesis. Since most ischemic
stroke patients received heparin during hospitalization, samples for longitudinal
analysis were treated with heparinase for one hour before starting RNA isolation
[116, 117].
cDNA synthesis was performed using the Exiqon Universal cDNA Synthesis
Kit II. The samples acquired in the previous RNA-isolation were diluted with 100µl
nuclease-free water. 3µl of each sample were transferred into Eppendorf DNA-
LoBind tubes. Each experiment included a non-template control (water) and an
RT- control, which lacked reverse transcriptase. To each sample, 1µl of Spike-in 6
(Exiqon Uni-Sp6 LNA PCR Primer set) was added as well as 2µl of reaction buffer
(provided in the kit, including deoxynucleotide triphosphates (dNTPs), buffer, and
cDNA-synthesis primers) and 3.5µl of nuclease free water. Samples were briefly
centrifuged at 2000g for a few seconds to spin down and mix ingredients. Sam-
ples were then incubated at 42°C for 1 hour and subsequently incubated at 95°C
for 5 minutes and stored at -80°C for long-term storage or at -20°C for short-term
storage until proceeding to RT-qPCR analysis.
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3.2.7 qPCR
cDNA samples were diluted in 150µl of nuclease-free water. 4µl of each sample,
5µl of ExiLENT SYBR Green Master Mix and 1µl of Primer (Exiqon microRNA
LNA PCR Primer Set) were pipetted into a well on a 386-well qPCR plate. Sam-
ples were analyzed using a Roche Light Cycler.
Denaturation 95°C, 10 minutes, ramp rate 4.8 °C/s
Amplification 45 cycles:
95 °C, 10 seconds, ramp rate 1.6 °C/s
60 °C, 1 minute, ramp rate 2.5 °C/s
Melting curve Continuously up to 95°C, ramp rate 0.11 °C/s
Cooling 37°C, 1 second, 2.5 °C/s
Table 3: qPCR cycles and temperatures
Ct-values of spike-in UniSp4 were used to normalize the results, by using a
median normalization method in the derivation sample, and a DDCt normaliza-
tion in the replication sample. Samples with Ct-values greater than 35 were set
to 40. When analyzing samples of the same cohort on more than one qPCR
plate, recombinant miRNA with determined copy numbers were used to adjust
the results.
3.2.8 Analysis of differences in blood sampling procedure
To identify ideal experimental conditions, we assessed the impact of various fac-
tors on miRNA yield. A 9ml blood sample of a healthy control person was drawn
into an EDTA-tube and separated into 12 separate 200µl samples. Subsequently,
each of them was treated differently. Samples were processed differently re-
garding incubation temperature, centrifugation steps to deplete platelets and an
additional centrifugation step prior to starting RNA isolation according to Figure
7. RNA-Isolation, cDNA synthesis and RT-qPCR were performed as described
above, and expression levels for miR-126-3p, miR-126-5p, miR-223-3p (high lev-
els in platelets, see results) and miR-122-5p (not present in platelets, see results)
were compared. Since all initial samples derived from the same plasma probe,
miRNA levels should be the same in all samples, and differences would indicate
confounding factors in our protocol.
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Figure 7: Different treatment of 12 samples with different protocols
The twelve samples differ in three factors: time of incubation immediately after
blood draw, platelet presence in the sample, and an extra centrifugation step
on day 2 before starting RNA-isolation. PRP = platelet-rich plasma. PPP =
platelet-poor plasma.
3.2.9 Fluorescent in-situ hybridization
Fluorescent in-situ hybridization (FISH) was performed using a three-day pro-
tocol, based on a previously published protocol by Chaudhuri et al [118]. For
the FISH analysis, we combined cell staining of neurons and astrocytes with
hybridization of miR-126-3p and miR-126-5p. Brain samples were cut into 5µm
sections using a Microtome. Four sections were fixed onto one slide and stored
at room temperature in the dark.
The slides were deparaffinized according to the following scheme:
- ’Xylene, 3 times, 5 min each
- 100% ethanol, twice, 5 min each
- 70% ethanol (diluted in DEPC-treated water), once, 5min
- 50% ethanol (diluted in DEPC-treated water), once, 5 min
- DEPC water, twice, 3 min each’ [118].
Antigen retrieval was performed by incubating the samples ’in 0,01M citrate
buffer pH = 6,4, for 40 min at 90°C’ [118] followed by 20 minutes at room
temperature. Before proceeding to ethylcarbodiimide (EDC) treatment, samples
were washed ’with TBS [(Tris-buffered saline)], 3 times, 3 min each’ [118].
Samples were incubated twice for 10 minutes each in Methylimidazole buffer
at room temperature, followed by a one-hour treatment with EDC solution in a
TBS-humidified chamber. Samples were washed with TBS/0.2% Glycine solution
for 5 minutes, followed by two washing steps in pure TBS for 5 minutes each.
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In the prehybridization step, the hybridization chamber was prepared ’by
placing 1X SSC-soaked Kimwipes at the bottom of the chamber’ [118]. The
hybridization buffer was heated up to 37°C and carefully pipetted onto the
slides. The slides were incubated for one hour at room temperature in an
SSC-humidified chamber.
The hybridization mix was prepared: Exiqon LNA FISH probes for the miRNAs
of interest, 5’- and 3’-digoxigenin labeled, were diluted in hybridization buffer up
to a total concentration of 4pmol in 2µl. The mix was incubated for 5 minutes at
’65°C for 5 min to ensure denaturation of probes’ [118] and then pipetted onto
the slides. The slides were incubated in an SSC-humidified chamber overnight at
specific hybridization temperatures (which is approximately 30°C lower than the







Scramble probe 87°C 57°C
Table 4: Incubation temperatures for miRNA FISH probes
The scramble probe, which only contained fragments, was used as an intrinsic
negative control. The slides were covered with wax and stored overnight.
The next morning, the slides were washed according to the following:
- ’Three times for 20 min each with 2x SSC at 42°
- Twice for 20 min each with 0.2x SSC at 42°’ [118]
The samples were washed in a solution of TBS/0.1% Tween for 15 minutes.
For blocking, the samples were incubated in blocking buffer for one hour at
room temperature in a PBS-humidified chamber. The primary antibody was di-
luted using blocking buffer at specific concentrations:
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Antibody Dilution
a-NeuN mouse (to stain neurons) 1:100
a-GFAP mouse (to stain astrocytes) 1:500
a-digoxigenin POD (to bind 3’- and 5’-
DIG labeled sites)
1:100
Table 5: Dilution of antibodies
The slides were left at 4°C overnight, allowing the antibodies to attach their
specific sites.
On the third day, the slides were washed ’twice in TBS for 2 min each at
room temperature’ [118]. The secondary antibody, anti-mouse Alexa Flour 488
(green, binding primary antibody for cell staining) was diluted in TBS at 1:500.
The slides were incubated for 1 hour in a TBS-humidified chamber and washed
twice for 2 minutes in TBS again. The Cy3-TSA secondary antibody (against
a-digoxigenin POD) was applied at a concentration of 1:100. The slides were
incubated again for 10 minutes in a TBS-humidified chamber and washed three
times for 5 minutes each in TBS. Subsequently, the slides were treated with
4’,6-Diamidino-2-Phenylindole (DAPI) at a dilution of 1:5000. The slides were
washed for 5 minutes in TBS, then quickly rinsed with DEPC-H2O and covered
using 22x50mm cover glasses and Flouromount mounting cover. The samples
were stored at 4°C in the dark until the Confocal microscope analysis.
Confocal microscopy was performed and analyzed using the ZEN Software
(Zeiss). Images were captured and extracted from Z-stacks. Maximum intensity
projection function was applied.
3.2.10 Statistics
Data were displayed as median±interquartile range or mean±standard error of the
mean. Differences in demographic factors and vascular risk factors in the deriva-
tion and replication sample were analyzed using Fisher’s exact test, student’s
t-test, and Chi2-test and ANOVA, respectively. The Mann-Whitney-U-test was
used for comparison of two groups, while more than two groups were compared
using 1-way ANOVA or Kruskal-Wallis-Test followed by Dunn’s multiple compar-
ison test. Matched data in the platelet spike-in experiment were analyzed using
the Friedman-Test. For multivariate analysis, Bonferroni correction for multiple
testing was used if indicated. Covariates in derivation and replication sample
were identified by backward stepwise regression and all results were adjusted
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with a linear multivariate model. In all experiments, a p-value < 0.05 was used
to determine statistical significance. Receiver operating characteristics were cre-
ated using random forest classification. All statistical analyses were performed by




4.1 Analysis of platelet-associated circulating miRNAs
in ischemic stroke patients
4.1.1 miRNA selection based on literature
Recent studies suggested that expression levels of various miRNAs might
correlate with platelet function and activation. Since platelet aggregation and
activation play an essential role in ischemic stroke pathophysiology, we decided
to focus on platelet-associated miRNAs in order to investigate miRNA expression
patterns and changes in plasma levels of circulating miRNAs after ischemic
stroke. Thus, we performed a literature search with search terms including
’microRNA’ or ’miRNA’ and ’platelet’ or ’thrombocyte’. Finally, we selected 12
miRNAs that had been described to correlate with platelet function and activation
in literature: miR-21-5p, miR-24-3p, miR-30b-5p, miR-92a-3p and miR-191-5p
based on a publication of Edelstein et al. in 2013 [119], miR-20b-5p [113], miR-
150-5p [120], miR-155-5p [121] and miR-197-3p [122], as well as miR-126-3p
and miR-126-5p [106, 107], and miR-223-3p. miR-223-3p has been shown
to bind the 3’-UTR of human P2Y12-receptor mRNA, thus regulating receptor
levels and platelet function [123], and shows significantly decreased plasma
levels in humans treated with clopidogrel, an ADP-antagonistic drug [124]. In
our platelet-related experiments, we used miR-223-3p as a positive control for
platelet association when analyzing other miRNAs. We also used miR-122-5p as
a negative control, since this miRNA has been suggested to be liver-specific and
not to be expressed in any other tissues [125].
In order to identify miRNAs that are expressed in a range of plasma levels that
could be reliably detected with our laboratory devices and experimental protocols,
we first quantified levels of the 12 miRNAs in a blood sample of a healthy human
volunteer. Since accuracy of qPCR measurement drastically decreases above
an average Ct-value of 35 [126], we only included the eight miRNAs that were
detected with a Ct-value below 35.
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Figure 8A: miRNA plasma levels in healthy human volunteers
Plasma levels of the 12 miRNAs selected in literature review in healthy hu-
man volunteers. Mean±SEM, results from five plasma samples of a single
healthy human volunteer.
Figure 8B: Selection of miRNAs
Selection of twelve miRNAs based on systematic review of literature. Eight
of them were reliably detectable in human control plasma by RT-qPCR.
4.1.2 Platelets contribute to miRNA plasma levels
Next, we investigated to what extent platelets contribute to plasma levels of these
miRNAs and thus performed a platelet spike-in experiment. In short, we isolated
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platelets from blood samples of healthy volunteers, spiked back various num-
bers of platelets into PPP and analyzed miRNA levels in those plasma samples.
Plasma levels of seven miRNAs increased significantly with increasing number
of platelets added to platelet-poor plasma: miR-21-5p, miR-24-3p, miR-30b-5p,
miR-92a-3p, miR-126-3p and miR-126-5p, as well as miR-223-3p. Liver-specific
miR-122-5p did not show significant changes with the number of platelets spiked
in. In addition, miR-150-5p levels did not show a significant increase with platelet
numbers and was therefore excluded from further experiments.
Figure 9A: miRNA levels increase with increasing platelet number
Positive control miR-223-3p shows a significant increase of circulating
miRNA levels with the number of platelets spiked into platelet-poor plasma
(A), while negative control miR-122-5p does not (B). miR-21-5p (C), miR-24-
3p (D), miR-30b-5p (E), miR-92a-3p (F), miR-126-3p (G) and miR-126-5p
(H) show a significant increase as well. miR-150-5p does not show a sig-
nificant change in this experiment. X-axis: percentages of original platelet
number spiked in. Friedman-Test. Mean±SEM, n=4. PRP = platelet-rich
plasma, PPP = platelet-poor plasma.
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Figure 9B: Selection of miRNAs
Seven miRNAs showed a significant increase with platelet numbers spiked
in in the platelet spike-in experiment.
4.1.3 Derivation sample
One of the main goals of our experiments was to test the hypothesis that platelet-
associated miRNAs show higher levels in patients with ischemic stroke compared
to healthy controls. After identifying seven miRNAs whose plasma levels increase
with platelet numbers in the platelet spike-in experiment, we aimed to analyze
whether those miRNAs would show changes in plasma levels of ischemic stroke
patients. The derivation sample included 60 stroke patients as well as 60 healthy
control subjects. The mean time from symptom onset to hospital arrival in the
ischemic stroke patient group was 5.4±4.3 hours and the mean infarct volume
was 18.6±40.8 ml (Table 6).
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Characteristics Healthy Controls Ischemic Stroke p-value
Demographics
Total 60 60
Age [years], mean (SD) 70.7 (9.3) 74.7 (12.5) 0.050
Female 34 (56.7) 26 (43.3) 0.201
Vascular Risk factors
Hypertension 38 (63.3) 50 (83.3) 0.022
Smoking History 21 (35) 28 (46.7) 0.265
Hypercholesterolemia 17 (28.3) 18 (30) 1
Obesity 7 (11.7) 11 (18.3) 0.444
Family History 4 (6.7) 11 (18.3) 0.095
Antiplatelet therapy 16 (26.7) 18 (30) 0.840
Previous TIA/stroke/MI 2 (3.3) 13 (21.7) 0.004
Ischemic Stroke n/a 60 (100) n/a
TMean [hours] Symptom
onset –> ED (SD)
n/a 5.4 (4.3) n/a
Table 6: Derivation sample
Demographic characteristics and vascular risk factors of stroke patients and
healthy control subjects included in the derivation sample. Fisher’s exact test,
except for Age (t-test). All values presented in n (%) unless indicated otherwise.
SD = standard deviation, MI = myocardial infarction, ED = arrival at emergency
department.
Plasma levels of five miRNAs were significantly elevated in acute ischemic
stroke patients compared to healthy controls in the derivation sample: miR-
21-5p (p=0.003), miR-24-3p (p < 0.0001), miR-126-3p (p=0.0004), miR-126-5p
(p=0.0001) and miR-223-3p (p=0.0001). miR-122-5p, the negative control, did
not show any alterations, nor did miR-30b-5p and miR-92a-3p.
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Figure 10: Derivation sample
Plasma levels of miR-223-3p (A, positive control), miR-21-5p (C), miR-24-
3p (D), miR-126-3p (G) and miR-126-5p (H) were significantly elevated in
acute ischemic stroke patients compared to healthy controls. miR-122-5p
(B), which served as a negative control, was not altered. Mann-Whitney-
U-Test, median±interquartile range, bars display 10th and 90th percentile,
n=60 per group.
Both hypertension and previous cardiovascular or cerebrovascular events
were significantly more prevalent in the ischemic stroke group compared to the
control group and were identified as potential confounders using backward step-
wise regression analysis. However, adjusting the results using a linear multivari-
ate model did not result in major changes of the p-values indicated above.
4.1.4 Replication of elevated plasma miRNA levels after ischemic stroke
and TIA
In order to validate the results in an independent and larger patient collective, 200
acute ischemic stroke patients, 100 healthy controls and 71 patients with TIA were
recruited for the replication sample. In this group, the mean time from symptom
onset to hospital arrival was 5.0±4.6 hours for stroke patients and 6.0±6.4 hours
for TIA patients, respectively.
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Characteristics Healthy Controls TIA Ischemic Stroke p-value
Demographics
Total 100 71 200
Age [years], mean (SD) 65.6 (13.4) 74.6 (12.4) 74.1 (13.4) < 0.0001
Female 65 (65) 38 (53.5) 87 (43.5) 0.003
Vascular Risk factors
Hypertension 35 (35) 54 (76.1) 157 (78.9) < 0.0001
Smoking History 35 (35) 30 (45.5) 74 (40.4) 0.256
Hypercholesterolemia 21 (21) 34 (47.9) 55 (27.8) 0.004
Obesity 19 (19.2) 13 (21.7) 28 (20.9) 0.927
Family History 9 (9) 9 (13.4) 23 (12.8) 0.006
Antiplatelet therapy 18 (18) 33 (46.5) 66 (33.5) 0.0004
Previous TIA/stroke/MI 7 (7) 35 (49.3) 65 (32.8) < 0.0001
Ischemic Stroke n/a n/a 200 (100) n/a
TMean [hours] Symptom
onset –> ED (SD)
n/a 6.0 (6.4) 5.0 (4.6) 0.176
Table 7: Replication sample
Demographic characteristics and vascular risk factors of stroke patients, TIA
patients and healthy control subjects included in the trial. Chi2-Test, except for
Age (ANOVA) and TMean symptom onset –> ED (t-test). All values presented
in n (%) unless indicated otherwise. SD = standard deviation, MI = myocardial
infarction, ED = arrival at emergency department.
Applying multivariable linear regression analysis adjusting for potential con-
founders age, sex, hypertension, antiplatelet therapy and previous cardiovascular
or cerebrovascular events, all five miRNAs that had shown significantly elevated
plasma levels in ischemic stroke patients in the derivation sample, showed ele-
vated plasma levels in the replication sample as well: miR-21-5p, miR-24-3p, miR-
126-3p, miR-126-5p, and miR-223-3p (all: p < 0.0001). Furthermore, plasma lev-
els of miR-126-3p and miR-223-3p were significantly elevated in ischemic stroke
patients compared to TIA patients, while the remaining miRNAs did not show
significant differences between those two groups.
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Figure 11A: Replication sample
All five miRNAs showed significantly elevated plasma levels in the stroke
group compared to the healthy control group (all: p < 0.0001). miR-126-
3p (C) and miR-223-3p (E) levels were also significantly elevated in acute
ischemic stroke patients compared to TIA patients. Mann-Whitney-U Test,
median±interquartile range, bars display 10th and 90th percentile. Con-
trols: n=100, TIA: n=71, Stroke: n=200. TIA = transient ischemic attack.
Figure 11B: Selection of miRNAs
Five platelet-associated miRNAs showed significantly elevated plasma lev-
els in acute ischemic stroke patients compared to healthy control subjects.
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4.1.5 miRNA plasma levels return to baseline levels quickly following is-
chemic stroke
After we detected a significant increase in plasma levels of several platelet-
associated circulating miRNAs on the day of symptom onset, we aimed at further
investigating the time course of plasma levels of those miRNAs, in order to assess
whether those changes are linked to the acute stage of stroke only, or if plasma
levels are further affected by secondary processes such as inflammation or tissue
reorganization. Thus, we performed longitudinal analyses of miRNA levels during
the acute phase (days 2, 3 and 7 or discharge day), and at 90 days after stroke.
Day 1 Day 2 Day 3 Day 7 (D/C) Day 90
ED Stroke Unit Stroke Unit Stroke Unit ISD
Outpatient Clinic
Patients 40 40 40 38 17
Controls 20
Table 8: Longitudinal follow-up of acute ischemic stroke patients
Number of patients included in the longitudinal analysis, time course and sites
of recruitment. ED = emergency department. ISD = Institute for Stroke and
Dementia Research. D/C = discharge.
For all five miRNAs except for miR-24-3p, we measured significantly elevated
plasma levels on day 1 that rapidly returned to control levels on day 2 and showed
no significant changes in the samples analyzed up to day 90. miR-24-3p re-
mained significantly elevated up to day 3 after stroke, and then returned to base-
line levels.
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Figure 12: Longitudinal analysis of miRNA plasma levels after stroke
All five miRNAs showed significantly elevated plasma levels on day 1 after
stroke. miRNA levels returned to normal on day 2, except for miR-24-3p (B)
levels, which only returned to baseline after day 3. 1-Way-ANOVA for mul-
tiple comparisons, median±interquartile range, bars display 10th and 90th
percentile. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Controls: n=20,
TIA: n=20, D1, D2, D3: n=40, D7: n=38, D90: n=17. HC = healthy controls,
D1-D90: day 1 – day 90.
4.1.6 Prior acetylsalicylic acid treatment has impact on miRNA plasma lev-
els
Several of the patients and control subjects included in our study had previously
been treated with acetylsalicylic acid (ASA). Here, we aimed at investigating the
impact of prior antiplatelet treatment on plasma levels of the platelet-linked miR-
NAs. We selected a group of stroke patients and healthy controls from the deriva-
tion sample that had been treated with ASA in the past seven days and compared
miRNA levels in both groups, as well as plasma levels in an equally sized group of
stroke patients and healthy controls without prior ASA treatment. The ASA group
included 19 patients and 15 healthy controls, the non-ASA group 21 patients and
25 healthy controls. When comparing ischemic stroke patients and healthy sub-
jects without prior ASA treatment, all five miRNAs showed significantly elevated
plasma levels in the stroke group. When comparing ischemic stroke patients and
healthy controls with prior ASA treatment, miR-21-5p and miR-223-3p did not.
42
4.1 Analysis of platelet-associated circulating miRNAs
in ischemic stroke patients 4 RESULTS
Figure 13: miRNA plasma levels in patients treated with and without ASA
miRNA plasma levels in ischemic stroke and healthy controls divided into two
groups, one of which had been taking ASA prior to the stroke. miR-21-5p
(A) and miR-223-3p (E) showed significantly elevated plasma levels in the
group without ASA, but not in the ASA group. miR-24-3p (B), miR-126-3p (C)
and miR-126-5p levels (D) were significantly increased in both no-ASA and
ASA group. Mann-Whitney-U Test, median±interquartile range. *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001. No ASA: Controls: n=25, Stroke: n=21.
ASA: Controls: n=15, Stroke: n=19. ASA = acetylsalicylic acid.
4.1.7 Diagnostic utility of miRNAs
To evaluate the utility of the identified miRNAs as diagnostic biomarkers in the
acute setting we performed a receiver operating characteristic (ROC) analysis.
The combination of miR-21-5p, miR-24-5p, miR-126-3p, miR-126-5p, and miR-
223-3p differentiated between ischemic stroke patients and healthy controls with
an area under the curve (AUC) of 0.82, which corresponds to a sensitivity of 84%
and a specificity of 68%. The AUC for distinguishing ischemic stroke and TIA
patients was 0.57 (sensitivity 39%, specificity 82%).
In a previous study [65], our group identified miR-125a-3p, miR-125b-3p
and miR-143-3p as potential diagnostic biomarkers for acute ischemic stroke.
The combined set of eight miRNAs, differentiating ischemic stroke patients and
healthy controls, resulted in an AUC of to 0.94, and did improve specificity (92%)
but not sensitivity (82%).
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Figure 14: Receiver operating characteristics
Receiver operating characteristics for (A) ischemic stroke vs. healthy con-
trols including miR-21-5p, miR-24-3p, miR-126-3p, miR-126-5p, and miR-
223-3p, (B) ischemic stroke vs. healthy controls combining the five miRNAs
with miR-125a-3p, miR-125b-5p and miR-143-3p that were identified in a
previous study done by our group. (C) Ischemic stroke vs. TIA including
miR-21-5p, miR-24-3p, miR-126-3p, miR-126-5p, and miR-223-3p. ROC =
receiver operating characteristics, AUC = area under the curve. TIA = tran-
sient ischemic attack. miR = microRNA.
4.1.8 Influence of differences in blood sampling procedure
An important characteristic of a useful diagnostic biomarker is being reliable
regardless of experimental conditions and laboratory setting [127]. In order
to examine the impact of different working conditions such as incubation time,
number of centrifugation steps, and platelet number present in the sample on
the results of our experiments, we compared 12 different plasma samples of one
single healthy human volunteer and treated each of them individually.
To significantly reduce the number of platelets in plasma samples, our RNA
isolation protocol included an additional centrifugation step of 2500g for 15
minutes. We first compared plasma levels of miR-126-3p, miR-126-5p, as
well as miR-223-3p and miR-122-5p with and without this step. miR-126-3p,
miR-126-5p and miR-223-3p showed significantly higher plasma levels in the
sample containing platelets, which was in line with the results of the platelet
spike-in experiment.
The plasma samples of study patients in our experiments were stored at -
80°C until further usage. Our protocol included an extra centrifugation step at
1500g for 10 minutes immediately after thawing. Comparing expression levels of
those samples with and without the centrifugation step did not show significant
differences in plasma levels.
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Figure 15A: Comparison of the extra centrifugation step vs. no centrifugation
Centrifugation step: 1500g for 10 minutes prior to RNA-isolation. miR-126-
3p (A), miR-126-5p (B), miR-223-3p (C) and miR-122-5p (D) plasma levels
in centrifuged plasma (C+) compared to plasma without extra centrifuga-
tion step (C-). None of the miRNAs showed significant changes with an
extra centrifugation. Mann-Whitney-U-Test, Mean±SEM, n=6.
Next, we aimed at investigating the impact of differences in working speed on
experimental results. The protocol for blood draw and sampling for study sub-
jects included a 30-minute incubation step at room temperature. We divided the
sample in three parts and left the samples at room temperature for different time
periods (0 minutes, 30 minutes, and 45 minutes). There were no significant dif-
ferences between the three time points in either of the four miRNAs.
Figure 15B: Different incubating times for plasma samples before processing
miR-126-3p (A), miR-126-5p (B), miR-223-3p (C) and miR-122-5p (D)
plasma levels after leaving plasma samples at room temperature for 0,
30 or 45 minutes prior to starting RNA isolation. No significant differences
could be observed, but it was remarkable that RNA yield was highest after
30 minutes for all miRNAs. Kruskal-Wallis-Test, Mean±SEM, n=4.
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4.2 Circulating miRNAs in experimental murine stroke models
4.2.1 miRNA plasma levels after induced murine stroke - photothrombosis
We considered the photothrombosis model as the most accurate experimental
murine stroke model available for studying platelet function and aggregation in
setting of an ischemic stroke, since it involves formation of a local thrombosis
induced by a fiber optic laser. Here, we compared plasma levels of the seven
miRNAs we initially selected for the platelet spike-in experiment, as well as
negative control miR-122-5p, after photothrombotic stroke compared to a sham
group.
None of the five miRNAs that were significantly altered in human stroke pa-
tients showed significant consistent alterations in murine plasma levels after
stroke. miR-21-5p levels, which had been significantly elevated in ischemic stroke
patients, even showed a significant decrease after photothrombosis-induced
stroke in mice.
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Figure 16: Photothrombosis model
Plasma levels of miRNAs in the photothrombosis stroke model, compared
to a sham group. miR-21-5p (A, p=0.0207), miR-30b-5p (C, p=0.0148) and
miR-150-5p (H, p=0.0281) showed a significant decrease in plasma levels
6 hours after murine stroke. Mann-Whitney-U-Test, Mean±SEM, n=8. PT =
photothrombosis.
4.2.2 miRNA analysis in murine brain samples
To test the hypothesis that the identified miRNAs are indeed platelet-associated
and not related to neurons or glial cell expression during an ischemic stroke,
we aimed at investigating miRNA expression in the brain. In a first approach,
we combined FISH with immunofluorescent labeling on brain sections of
dMCAo-treated mice. We labeled neurons with NeuN, astrocytes with GFAP and
miRNAs with probes in the same sample, to assess whether a cell-type specific
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expression of miRNAs can be detected.
In all stainings, scramble miRNA 3’-5’-digoxigenin-labeled probes served as
a negative control. Areas with enhanced miR-126-3p staining did not colocalize
with NeuN-labeled neurons in healthy brain tissue.
Figure 17: miR-126-3p + neuron staining in healthy murine brain tissue
Alexa Flour 488 staining of NeuN-labeled neurons, Cy3 staining of
digoxigenin-labeled miR-126-3p and scramble miRNA as negative control,
respectively, DAPI staining of nucleoli and merge in healthy murine brain
tissue. Scrbl = Scramble miRNA probe.
When staining astrocytes with GFAP instead, no colocalization with areas of
enhanced miR-126-3p expression could be detected either.
Figure 18: miR-126-3p + astrocyte staining in healthy murine brain tissue
Alexa Flour 488 staining of GFAP-labeled astrocytes, Cy3 staining of
digoxigenin-labeled miR-126-3p and Scramble miRNA as negative control,
respectively, DAPI staining of nucleoli and merge in healthy murine brain
tissue. Scrbl = Scramble miRNA probe.
In the murine stroke core area, stains showed scattered nucleoli and destroyed
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neurons or astrocytes, respectively, alongside several remaining cells and frag-
ments. miR-126-3p showed unspecific enhancement with no association to de-
graded cells.
Figure 19: miR-126-3p + neuron and astrocyte staining in murine stroke core area
Alexa Flour 488 staining of NeuN-labeled neurons and GFAP-labeled astro-
cytes, respectively, Cy3 staining of digoxigenin-labeled miR-126-3p, DAPI





Our study identifies a set of five circulating platelet-associated miRNAs, which
show differential expression in the acute phase after ischemic stroke. miR-21-5p,
miR-24-3p, miR-126-3p, miR-126-5p and miR-223-3p showed increased plasma
levels in both derivation and replication sample in ischemic stroke patients com-
pared to healthy controls. miR-126-3p and miR-223-3p also showed significantly
elevated plasma levels in comparison to plasma levels in TIA patients.
A longitudinal analysis of those miRNAs on days 2, 3, 7 and 90 after stroke
showed that plasma levels quickly returned to baseline levels on day 2 after
stroke and did not show any significant changes afterwards, with the exception
of miR-24-3p, whose levels remained significantly elevated until day 3. In terms
of discriminating between ischemic stroke and healthy controls, a combination of
these miRNAs showed an AUC of 0.82, translating into a sensitivity of 84% and a
specificity of 68%, which is higher than the sensitivity and specificity of CT scans
in the early hours after an ischemic stroke [128]. When differentiating between
ischemic stroke patients and TIA patients, the AUC was 0.57, which corresponds
to a sensitivity of 39% and specificity of 82%. After analyzing the AUC of our
platelet-associated miRNAs, we combined the five miRNAs that we identified in
our previous publication [65], with the five miRNAs of the platelet-association
study. This resulted in a total AUC of 0.94 (sensitivity 82%, specificity 92%).
All five miRNAs also showed increasing plasma levels with the number of
platelets added in a platelet spike-in experiment. When comparing ischemic
stroke patients and healthy controls who had been taking ASA in the previous
seven days, miR-21-5p and miR-223-5p did not show significant changes in
plasma levels in the ischemic stroke group anymore, suggesting an impact of
platelets on miRNA plasma levels.
When analyzing differences in working speed and impact of differential
centrifugation steps, minor changes in protocols of blood sampling and RNA
isolation did not lead to significantly altered miRNA yield or results. However, as
suggested by the platelet spike-in experiment, platelet numbers in the plasma
samples had a significant impact on miRNA levels.
In the experimental murine photothrombosis model, none of the five miRNAs
showed a significant increase or directionality in line with the findings in human
ischemic stroke patients. Combined FISH and immunofluorescent labeling did
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not show a colocalization of miR-126-3p expression with neurons or astrocytes
in the murine brain.
Diagnostic utility of platelet-associated miRNAs in a clinical setting
To our knowledge, none of the blood-based biomarkers assessed for their
diagnostic utility have surpassed the receiver operating characteristics of the
identified miRNAs so far. Blood-based proteins such as GFAP, S100B or NSE
lack sensitivity especially in the early phase of ischemic stroke, since they peak
on day 2 after ischemic stroke, or later [60, 61, 63]. Recent studies have identified
miRNAs that show specific expression patterns and elevation in plasma levels
in the first hour after myocardial infarction [129, 130], stressing the potential of
miRNAs as diagnostic biomarkers in the acute phase.
Currently, CT imaging is the first choice in diagnostics of acute ischemic
stroke [131]. However, since CT scans only show a sensitivity of about 60%
[128], the miRNAs identified in our study, who showed a sensitivity of 84% in
the acute phase, may have diagnostic potential for early ischemic strokes in the
future. In order to replace or support neuroimaging as the primary diagnostic
measure in stroke diagnostics, it would be essential to find an assay that is able
to quantify miRNA levels within a few minutes in order to contribute to acute
decision making in the initial stroke phase to the same extent as CT scans
currently do. So far, the mean time from blood draw to retrieving miRNA level
results from qPCR analysis is 5-6 hours, an issue that needs to be resolved in
order to approach CT’s usefulness in acute diagnostics.
In order to ensure specificity, further studies might address whether a similar
miRNA expression profile is present in other neurological diseases such as
intracranial hemorrhages, seizures, migraines or head trauma, which pose
important differential diagnoses in setting of a patient with sudden onset of
neurological symptoms. In addition, the differentiation between ischemic and
hemorrhagic stroke is of crucial importance for a diagnostic biomarker used in the
acute clinical setting. Some miRNAs have been identified to show significantly
elevated plasma levels in hemorrhagic stroke patients compared to healthy
controls [132]. If, in the future, further experiments show that our miRNAs show
a similar expression pattern in hemorrhagic stroke as they do in ischemic stroke,
adding more miRNAs to the analysis may be an option. Since the miRNAs
identified in our experiment are linked to platelet activation or aggregation, it
is possible that these miRNAs show a similar elevation of plasma levels in
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other pathologies involving thrombus or embolus formation, such as myocardial
infarctions, pulmonary embolisms or deep vein thrombosis. However, since
these patients can usually be distinguished from stroke patients by thorough
clinical examination only, this might not necessarily restrict the potential of the
miRNAs. A disease that might, in some cases, be confounded with ischemic
stroke patients by clinical presentation could be cerebral vein thrombosis, and
miRNA plasma levels of those patients are yet to be examined.
In our experiments, miR-126-3p and miR-223-3p were shown to be signifi-
cantly altered in ischemic stroke patients in comparison to TIA patients. Being
able to distinguish an ischemic stroke patient from a TIA patient would remarkably
influence the clinical decision for or against systemic lysis therapy. However, the
sensitivity of 39% does not suffice in order to serve as a diagnostic biomarker for
this specific clinical challenge. So far, to our knowledge, other attempts to find a
biomarker that could successfully differentiate between TIA and ischemic stroke
were also unsuccessful [133].
Four of the five miRNAs identified in our study showed elevated plasma
levels after ischemic stroke that quickly returned to baseline levels on day 2
after stroke. In the past few years, many studies have focused on treatment of
stroke patients with unknown onset time of symptoms, such as wake-up strokes.
Further analyses of the exact times of rise and decrease of circulating miRNAs
on day 1 after stroke might reveal a specific time course that might enable us
to draw conclusions on the time of stroke onset retrospectively. Being able to
estimate the time of stroke onset and thus determining whether a patient is
eligible for intravenous thrombolysis would remarkably improve treatment options
of ischemic stroke patients with unknown symptom onset.
Recently, numerous publications have focused on plasma levels of miR-
NAs, but since every laboratory uses different procedures, working conditions
and protocols, it still needs to be shown to what extent results from different
laboratories are comparable and replicable, and how much of the changes in
miRNA levels in human plasma can be traced back to working conditions, cell
degradation or cell loss. When analyzing differences in working speed, differ-
ential centrifugation steps and number of platelets present in plasma samples
during RNA isolation, plasma levels in platelet-rich plasma were significantly
higher than in platelet-poor plasma in miR-126-3p, miR-126-5p and miR-223-3p.
No significant differences could be observed for miR-122-5p. This is in line
with our previous experiments and further emphasizes the fact that in studies
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researching cardiovascular or cerebrovascular pathologies, the contribution of
platelets to circulating miRNA levels needs to be carefully considered in order to
avoid confounding of results. None of the miRNAs examined showed significant
differences in results after an extra centrifugation step or after different incubation
times immediately after blood draw. This suggests potential for the miRNAs
to serve as reliable biomarkers, even when measured in different settings and
laboratories. However, standardized experimental conditions, equipment and
cut-off levels would be required prior to establishing miRNAs as blood-based
biomarkers in a clinical setting. Possibly confounding or complicating factors that
were not addressed in our experiments may include hemolysis during blood draw
or remainder of subcellular or cellular components in the samples [134].
The results of the longitudinal analysis suggest that the release of miRNAs
into the circulation after ischemic stroke is linked to the acute stage and does
not seem to be influenced by later molecular processes in stroke such as cell
damage, tissue reorganization or inflammation. Further analyses of processes of
secretion, release and regulation of platelet-associated miRNAs will be essential
in order to determine their potential in diagnostics.
Platelets: a major source of circulating miRNAs
Underlying molecular processes of regulation, secretion and cellular sources of
the miRNAs identified in setting of ischemic stroke are yet to be discovered. As a
first approach, we identified platelets as major sources of all five miRNAs in our
experiments.
In the platelet spike-in experiment, plasma levels of all five miRNAs depended
on the number of platelets spiked in. These findings are in line with those of
Kaudewitz et. al. in 2016, who discovered miR-223-3p and miR-126-3p to be
dependent on platelet numbers in a platelet spike-in experiment. This study also
revealed that miR-126-3p and miR-223-3p, and, to a lesser extent, miR-21-5p
and miR-24-3p ’correlated with plasma levels of P-selectin, platelet factor 4 and
platelet basic protein in the population-based Bruneck study (n=669)’ [113].
These results, in combination with our findings in ischemic stroke patients, sug-
gest a strong link to platelet function for the miRNAs identified and underline the
importance of further investigating molecular mechanisms not only in ischemic
stroke, but in other pathologies involving platelet aggregation and thrombosis.
In the ischemic stroke patient group, negative control miR-122-5p did not
53
5 DISCUSSION
show significant changes compared to the control group, nor did miR-150-5p,
which has been shown not to be associated with the number of platelets added
in the platelet spike-in experiment. Those findings further support the hypothesis
that the elevated plasma levels of platelet-associated miRNAs might occur due
to an association with thrombus formation, platelet aggregation or activation pro-
cesses in ischemic stroke pathophysiology. However, these data do not enable
us to draw conclusions about causality: It is possible that the five miRNAs are, in
fact, actively secreted or released from platelets during activation. Nonetheless,
it is also possible that plasma levels of these miRNAs had been elevated prior
to the stroke, due to increased platelet activation status in patients with future
ischemic stroke, or that increased plasma levels of platelet-associated miRNAs
might even be associated with a higher risk for ischemic stroke. Analyzing
whether there is a correlation between the platelet-associated miRNAs identified
and thrombus size and clot burden in the ischemic stroke group could be a
possible next step towards investigating the role of the elevated miRNA plasma
levels in the acute stroke setting. The same applies for correlation for infarct
volumes, but might be of limited importance for a diagnostic marker for ischemic
stroke, as small strokes in eloquent areas can cause more damage to the patient
than a large stroke in a different part of the brain [54].
When our experiments revealed that platelets are a major cell type contribut-
ing to circulating plasma miRNA levels in ischemic stroke patients, the question
was raised whether prior antiplatelet treatment, which is common especially in
patients with cardiovascular risk factors and therefore also in the study cohort,
has an influence on miRNA levels in those subjects. When comparing miRNA
plasma levels in ischemic stroke patients and healthy controls who all had
been taking ASA in the week prior to the blood draw, no significant elevation
of miR-21-5p and miR-223-3p plasma levels could be observed, in contrast to
the group without ASA treatment. Plasma levels of miR-24-3p, miR-126-3p and
miR-126-5p were still significantly elevated but showed a more discrete elevation
than in the original experiment.
These findings were in line with the identification of prior antiplatelet therapy
as a relevant covariate in the replication sample, revealing that antiplatelet
therapy might affect the release of platelet-associated miRNAs, and that results
obtained in experiments that involve platelet-linked miRNAs need to be adjusted
by multivariate analysis.
The effect of antiplatelet therapy on circulating miRNA levels has previously
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been addressed in several studies. In 2013, Willeit et al. [106] analyzed 8
miRNAs, which we also assessed in our experiments, in 9 healthy volunteers and
compared miRNA levels after no treatment, or treatment with 10mg prasugrel,
10mg prasugrel + 75mg ASA or 10mg prasugrel + 300mg ASA. In this first
experiment, miR-21-5p, miR-24-3p, miR-126-3p and miR-223-3p showed a
negative correlation with increasing dosage of antiplatelet therapy. Interestingly,
a negative correlation with antiplatelet therapy could also be detected in miR-
20b-5p, miR-150-5p, miR-191-5p and miR-197-3p, all of which are miRNAs that
we had excluded because of lacking correlation with platelet numbers in the
platelet spike-in experiment or because the concentration in plasma samples of
healthy subjects was not sufficient to be reliably detected in the plasma samples
used in our experiments. This suggests that other miRNAs such as miR-150-5p,
even though not directly involved in platelet function, play an important role in
mechanisms leading to or following platelet aggregation or platelet activation and
might also be related to the pathophysiological processes in ischemic stroke and
other cardiovascular pathologies, which yet needs to be investigated.
De Boer et al. confirmed in an in vitro experiment that miR-126-3p is released
into plasma upon platelet activation, and that plasma levels of this miRNA
correlate with platelet activation in diabetes mellitus type 2 patients. When
administering ASA, circulating miR-126-3p levels were significantly lower in
comparison to a placebo treatment [135].
Results of these studies implicate that the effects of antiplatelet drugs on
circulating plasma miRNA levels are a crucial factor in the assessment of miRNAs
in cardiovascular and cerebrovascular diseases and must be taken into account
in future studies and experiments.
Plasma levels and cellular sources of miRNAs in murine stroke models
When our experiments showed that platelets are a major contributor of circulating
miRNAs in blood plasma in humans, we became interested in discovering
whether we could reproduce those findings in murine models, which could be a
step towards further investigating molecular and pathophysiological mechanisms
in the future. There is a variety of experimental murine stroke models, which
all intend to reflect different types or different pathophysiological processes of
human stroke. For our experiments, we analyzed the miRNAs selected for our
study in the photothrombosis model, which involves platelet aggregation and
thrombus formation induced by a laser. In this experiment, none of the five
55
5 DISCUSSION
miRNAs that are differentially expressed in human ischemic stroke showed
significant alterations in the photothrombosis stroke model, compared to a
sham group. The only exception to this was miR-21-5p, which was significantly
decreased in the stroke model compared to the sham group, contradicting the
increase in plasma levels in human ischemic stroke patients. In addition, plasma
levels of miR-30b-5p and miR-150-5p were significantly decreased in this model,
contradicting the results in the human experiment as well.
To our knowledge, there are no similar studies that assess the expression of
miRNAs in a murine photothrombosis stroke model. However, there are some
studies that use middle cerebral artery occlusion (MCAo) models to assess
alterations in miRNA expression levels: in 2008, Jeyaseelan et al. [136] identified
aberrantly expressed miRNAs in rat blood and brains after transient ischemia was
induced by MCAo, which included miR-150-5p and miR-191-5p. Both miRNAs
were upregulated at both 24 and 48 hours after induced stroke, however, since
we analyzed murine miRNA plasma levels at 6 hours after induced stroke,
those findings are of limited comparability. Dharap et al. [137] identified several
miRNAs that are up- or downregulated at 3, 6, 12, 24 and 72h after MCAo,
but none of the miRNAs that were differentially expressed had been part of our
experiments.
We were not able to find a miRNA that showed consistent changes and direc-
tionality in human ischemic stroke patients and mice with induced experimental
stroke by the photothrombosis model. One reason for this could be traced back
to slightly different nucleotide sequences in human and murine miRNAs, as
well as differences in posttranscriptional regulations in both species [125]. As a
second reason, all experimental murine stroke models can only partially mimic
the pathophysiological events that occur in a human ischemic stroke, and it
is possible that the processes in ischemic stroke patients that lead to platelet
aggregation, thrombus formation and miRNA release are not properly reflected
by the models we used in our experiments [138]. Experiments done in a different
species are always limited, because of substantial differences in physiology and
pathophysiology inbetween different species, which cannot always be overcome
by drafting an experimental animal model.
However, further studying platelet-linked miRNAs and pathophysiological
processes as well as further improving experimental murine stroke models may
eventually lead to the identification of miRNAs whose function can successfully
be reflected in murine stroke models. Studies done on miRNAs in acute my-
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ocardial infarction are a good example: miR-208a and miR-499 have been found
to be elevated in acute myocardial infarctions and have potential as diagnostic
biomarkers [99, 105]. Xiao et al. showed that plasma levels of both miRNAs
are accordingly elevated in mice with induced myocardial infarction by coronary
artery ligation after 4 and 24 hours [139].
When combining FISH of specific cell types with immunofluorescent labeling
of miRNAs, no colocalization of miR-126-3p expression with neurons or astro-
cytes could be observed neither in healthy brain tissue, nor in the infarct core
area of mice with induced experimental stroke. This may suggest that plasma
levels of those miRNAs are mainly linked to platelet function and aggregation
and not be influenced by active or passive secretion by brain cells. However,
in contrast, a study performed on rat brain sections showed that miR-21-5p
expression is upregulated in neurons in the ischemic area [140]. Furthermore,
recent studies found miR-126-3p to be expressed in neurons, and involved in
their function in humans [141, 142], miR-223-3p levels are elevated in neurons
in autoimmune encephalomyelitis [143] and miR-21-5p has been found to be
expressed in oligodendrocytes [144]. Thus, future experiments will require opti-
mization of experimental conditions and the identification of accurate incubation
temperatures and times to ensure specific staining and labeling of cells and
miRNAs, in order to further examine cell-specific expression in the human and
murine brain.
In order to find a murine stroke model that appropriately reflects pathophys-
iological processes in human ischemic stroke as well as changes in plasma
levels of platelet-associated miRNAs, further investigations of pathophysiology
by using microRNA-antagonists (antagomiRs) and by extracting platelets or brain
cells from murine stroke models might be necessary. Another approach could
be to induce a stroke in ApoE-deficient mice in order to improve reflection of the
atherosclerotic and endothelial processes leading to a stroke in humans.
Pathophysiological processes in ischemic stroke involving platelet-linked
miRNAs
Besides their occurrence in platelets, the miRNAs identified are involved in
biological processes in the blood vessels as well as in pathophysiological
processes in ischemic stroke. A previous study showed that ’miR-21 overex-
pression reduced endothelial cell proliferation, migration and the ability of these
cells to form tubes’ [145]. In line with our findings, miR-21-5p and miR-24-3p
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have been described as potential diagnostic biomarkers for ischemic stroke
and atherosclerosis in two recent publications [146, 147]. miR-24-3p has
been shown to be involved in angiogenesis as well [148], while miR-126-3p
’mediates developmental angiogenesis in vivo’ [149]. It has also been shown
to be atheroprotective [150]. Levels of this miRNA correlate with the severity of
cerebral atherosclerosis [151], and ’with lower disease risk, decreased disease
severity, and reduced inflammatory cytokines in AIS [(acute ischemic stroke)]
patients’ [152]. Underlining the association to platelets described in our exper-
iments, both miR-126-3p and miR-223-3p are involved in regulation of platelet
reactivity and function in diabetes mellitus patients [111]. miR-126-3p and
miR-126-5p are two of the most abundantly expressed miRNAs in endothelial
cells [150]. Schober et al. found that miR-126-5p prevents the formation of
atherosclerotic lesions and is substantial to endothelial repair. In addition, his
group discovered that miR-126-5p expression in endothelial cells is induced by
vascular shear stress [89]. miR-223-3p has been widely described and linked
to platelet function and aggregation in recent literature: it targets the P2Y12-
receptor [123] on platelets which plays a major role in the process of platelet
aggregation [153]. Mice with antagonized miR-223-3p form larger thrombi in
comparison to wild type mice [111], and miR-223-3p influences response to
clopidogrel [124]. In an analysis of 50 human ischemic stroke patients, Chen
et al. showed that ’increased circulating exosomal miR-223 is associated with
acute ischemic stroke occurrence, stroke severity, and short-term outcome’ [154].
Taking all of these findings into account, we cannot know with absolute
certainty whether altered miRNA plasma expression profiles are directly involved
in platelet activation or aggregation, and if alterations are cause or result of
platelet function. Furthermore, it is possible that the miRNAs indirectly affect
platelet function by being involved in endothelial processes which lead to platelet
aggregation. Considering the complexity of the pathophysiology leading to
atherosclerosis, platelet activation as well as to ischemic stroke and other car-
diovascular pathologies, the exact role of miRNAs remains unclear and further
investigation is required in the future.
Strengths and limitations
To our knowledge, our study presents the analysis of miRNA levels after is-
chemic stroke with the largest patient number in current literature. Overall, our
study included almost 500 patients acquired over the time span of three years.
Significant elevation of all miRNAs in the derivation sample after ischemic stroke
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could be replicated in the replication sample. Not only did we analyze expression
levels in comparison to healthy controls, but we also included TIA patients, since
reliably diagnosing a TIA and distinguishing it from an ischemic stroke is an
essential part in the decision making for the most appropriate therapy. In our
analysis, we thoroughly ruled out confounding factors: In the derivation cohort,
we excluded patients with prior treatment with antiplatelet drugs or heparin,
recent cardiovascular events, signs for silent CNS infarctions and recent major
diseases or surgeries. In both derivation and replication sample, we carefully
identified relevant covariates such as demographic factors and vascular risk
factors, which we accounted for in a multivariate statistical model. None of our
study subjects had been treated with heparin in the weeks prior to the blood
draw, thus interference of heparin with the qPCR enzymes was avoided. Upon
hospital arrival, blood of the ischemic stroke and TIA patients was immediately
drawn, prior to starting diagnostic and therapeutic measures, which allowed
us to analyze miRNA plasma levels in the very early hours after symptom
onset. Involving ischemic stroke patients and their relatives as healthy controls
in frequent follow-up exams at the outpatient clinic enabled us to follow up on
miRNA expression and the dynamics up to 90 days after stroke. All experiments
were performed by adding a ’normalization control [that] is stably expressed
and not affected by experimental conditions or clinical parameters’ [108]. In our
experiments, synthetic intrinsic spike-in controls such as UniSp4 and UniSp6
were used, as well as normalization to average Ct-values of all analyzed miRNAs
[155]. All of our experiments were performed using a double randomization:
Ischemic stroke patients, TIA patients and healthy control subjects were ana-
lyzed in randomly assigned groups on cDNA and qPCR plates. During the entire
experiment, the patient identification remained unknown to the experimenter, as
well as the origin (stroke, TIA or control) of the sample.
Our experiments also have limitations. All of our study subjects were recruited
from one single hospital, which might lead to selection bias of the study group.
As only a part of the initial patients returned for the follow-up exam on day 90
after stroke, it cannot be excluded that some patients did not return due to a
bad outcome or severe disability, thus biasing the results. We therefore cannot
exclude that miRNA levels on day 90 are different in patients with large and
severe infarctions. In addition, miRNAs are sensitive to degradation during
RNA-isolation, reverse transcription and qPCR, and might have been influenced
by differing experimental conditions such as waiting times or room temperature
[115]. By performing several pre-tests prior to analyzing samples of the study
cohorts, we standardized experimental procedures and protocols and identified
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possible confounding variates. When analyzing the replication sample or the
longitudinal analysis, the number of study subjects, and hence samples, was too
large to fit on one single qPCR plate. In order to avoid the results being biased
by this, we added recombinant miRNA samples with determined miRNA copy
numbers on each plate and normalized the results to changes that might have
influenced the results during qPCR. Even though our results showed significantly
elevated miRNA plasma levels in the early hours after symptom onset, we cannot
exclude that those levels had been elevated prior to the stroke. However, since
four of the five miRNAs showed plasma levels that quickly returned to normal on
day 2, it is likely that the changes in miRNA levels are related to the acute event
of stroke onset.
Conclusion
In conclusion, circulating plasma levels of platelet-associated miRNAs are sig-
nificantly elevated in ischemic stroke patients and healthy controls. Overall, we
consider these miRNAs to have potential as diagnostic biomarkers for acute is-




Stroke is one of the leading causes of death and disability worldwide and requires
fast diagnosis and therapy in order to minimize permanent brain damage. So
far, neuroimaging is the best and most accurate way to diagnose an ischemic
stroke, and CT scans can rule out a hemorrhagic stroke with high sensitivity.
However, CT lacks sensitivity in distinguishing an ischemic stroke from stroke
mimics such as seizures, migraines or cerebral infections in the early hours after
stroke onset. There are recent approaches to find a diagnostic blood-based
biomarker for ischemic stroke as well as for transient ischemic attack (TIA), such
as neuron-specific enolase (NSE), S100B or glial fibrillary acidic protein (GFAP),
or coagulation or inflammatory markers, but their potential as diagnostic biomark-
ers is limited due to lacking sensitivity or a delayed response after symptom onset.
microRNAs (miRNAs) are small, non-coding RNAs, that can circulate in the
blood with high stability and cell- and tissue-specific expression patterns. Platelet
aggregation and thrombus formation are essential pathophysiological processes
in both embolic and thrombotic ischemic stroke. For many miRNAs, platelets
have been identified as a major source. Thus, the goal of this dissertation was to
analyze plasma levels of platelet-associated miRNAs in ischemic stroke and TIA
patients, to assess their potential as diagnostic biomarkers and to investigate
molecular mechanisms of miRNA release and cellular sources in murine stroke
models.
First, we selected miRNAs that had been described to be associated with
platelets in a systemic literature search. We quantified plasma levels of those
miRNAs in a healthy human volunteer and selected eight miRNAs for subsequent
experiments. In a platelet spike-in experiment, we compared miRNA plasma
levels in platelet-poor plasma (PPP) with different numbers of platelets spiked in
to platelet-rich plasma (PRP), and identified seven miRNAs whose plasma levels
depended on the number of platelets spiked in. Next, we compared plasma
levels of the miRNAs in 60 ischemic stroke patients to 60 healthy controls in
the derivation sample. The five miRNAs who showed significantly elevated
plasma levels in the ischemic stroke group (miR-21-5p, miR-24-3p, miR-126-3p,
miR-126-5p and miR-223-3p) also showed significantly elevated plasma levels
in the replication sample, which included 200 ischemic stroke patients and
100 healthy controls. miR-126-3p and miR-223-3p also showed significantly
elevated plasma levels in ischemic stroke patients compared to TIA patients. A
longitudinal analysis showed that all miRNAs returned to baseline levels on day
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2 after stroke, with the exception of miR-24-3p, whose plasma levels remained
elevated up to day 3. miR-21-5p and miR-223-3p did not show elevated plasma
levels in a group of ischemic stroke patients compared to healthy controls, all
of which had been treated with acetylsalicylic acid (ASA) before, suggesting a
platelet aggregation link to miRNA release. A receiver operating characteristics
analysis of the five miRNAs resulted in a combined sensitivity of 84%, which
is higher than the sensitivity of CT imaging in the early hours after symptom onset.
Plasma levels of the platelet-associated miRNAs did not show similar signif-
icant changes or directionality in a murine experimental stroke model including
photothrombosis. Combined fluorescent in-situ hybridization and immunofluo-
rescent labeling did not show a colocalization of miR-126-3p and neurons or
astrocytes, respectively.
Overall, we suggest that platelet-associated miRNAs are potential diagnostic




Der Schlaganfall ist eine der häufigsten Todesursachen weltweit sowie eine der
führenden Ursachen für eine bleibende Behinderung. Um bleibende Gehirn-
schäden zu verhindern, sind eine schnelle Diagnose und Therapie essenziell.
Aktuell sind bildgebende Verfahren die beste und genaueste Methode, um
einen ischämischen Schlaganfall zu diagnostizieren. Die CT-Bildgebung kann
einen hämorrhagischen Schlaganfall mit hoher Sensitivität ausschließen. Bei
der differentialdiagnostischen Abgrenzung eines ischämischen Schlaganfalls
von sogenannten ’Stroke mimics’ wie Krampfanfällen, Migräneattacken oder
zerebralen Infektionen ist die Sensitivität jedoch deutlich geringer, besonders in
den ersten Stunden nach Auftreten der Symptomatik. In letzter Zeit beschäftigten
sich zahlreiche Studien mit der Suche nach einem Biomarker, sowohl für den
ischämischen Schlaganfall als auch für die transiente ischämische Attacke (TIA)
im Blut. Zahlreiche neuronale und gliale Marker wie die neuronenspezifische
Enolase (NSE), S100B oder saures Gliafaserprotein (GFAP), Gerinnungs- sowie
Entzündungsmarker wurden untersucht, zeigten jedoch aufgrund geringerer
Sensitivität sowie verspäteter Antwort nach Auftreten der Symptomatik nur ein
eingeschränktes Potential als diagnostischer Biomarker.
microRNAs (miRNAs) sind kleine, nicht-kodierende RNAs, die im Blut mit ho-
her Stabilität zirkulieren, sowie zell- und gewebespezifische Expressionsmuster
zeigen. Thrombozytenaggregation und Thrombusbildung sind essenzielle
pathophysiologische Prozesse sowohl beim embolischen als auch beim throm-
botischen ischämischen Schlaganfall. Da Thrombozyten in der Literatur als
Quelle zahlreicher miRNAs identifiziert wurden, war das Ziel der Dissertation 1.
die Untersuchung der Plasmakonzentration von mit Thrombozyten assoziierten
miRNAs in Patienten mit ischämischem Schlaganfall und TIA verglichen mit
Kontrollen, 2. ihr Potential als diagnostische Biomarker zu analysieren und 3. in
Mausmodellen die molekularen Mechanismen und den zellulären Ursprung der
miRNAs zu untersuchen.
Zuerst wurden in einer systemischen Literaturrecherche miRNAs ausgewählt,
die mit Thrombozyten oder deren Funktion assoziiert sind. Die Konzen-
trationen dieser miRNAs wurden zunächst an einem gesunden Probanden
untersucht. Anschließend wurden acht miRNAs mit zuverlässig nachweisbaren
Plasmakonzentrationen für die weiteren Experimente ausgewählt. In einem
sogenannten ’Platelet Spike-in Experiment’ wurde die Plasmakonzentration
in thrombozytenfreiem Plasma, zu dem verschiedene Konzentrationen von
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Thrombozyten hinzugefügt wurden, mit thrombozytenreichem Plasma ver-
glichen. Es konnten sieben miRNAs identifiziert werden, deren Konzentration mit
zunehmender Thrombozytenanzahl in der Probe korrelierte.
Danach wurde die Plasmakonzentration dieser miRNAs in 60 Patienten mit
ischämischem Schlaganfall im Vergleich zu 60 gesunden Kontrollprobanden
analysiert. Die Erhöhung der Konzentration von fünf miRNAs (miR-21-5p,
miR-24-3p, miR-126-3p, miR-126-5p und miR-223-3p) in der Schlaganfall-
Gruppe konnte in einer weiteren Versuchsgruppe mit 200 Schlaganfallpatienten
und 100 Kontrollen bestätigt werden. In dieser Gruppe zeigte sich auch eine
signifikante Erhöhung von miR-126-3p und miR-223-3p in Schlaganfallpatienten
im Vergleich zu Patienten mit einer TIA. Eine longitudinale Analyse zeigte,
dass die Konzentration von vier der fünf miRNAs schon am Tag 2 nach dem
ischämischen Schlaganfall wieder zu normalen Plasmaspiegeln zurückkehrte,
nur miR-24-3p zeigte noch eine signifikant erhöhte Plasmakonzentration bis zu
Tag 3 nach Auftreten der ersten Symptome. In einer Versuchsgruppe, in der
alle Teilnehmer zuvor mit Acetylsalicylsäure (ASS) behandelt worden waren,
war die Konzentration von miR-21-5p und miR-223-3p in der ischämischen
Schlaganfallgruppe im Vergleich zur gesunden Kontrollgruppe nicht mehr erhöht,
was auf einen starken Zusammenhang der Thrombozytenaggregation mit einer
erhöhten Expression der miRNAs schließen lässt.
Eine ROC-Analyse ergab bei Kombination der fünf miRNAs bei Vergleich von
ischämischem Schlaganfall zu gesunden Kontrollen eine Sensitivität von 84%.
Diese ist höher als die Sensitivität der CT-Bildgebung in den ersten Stunden nach
Auftreten des Schlaganfalls. Im experimentellen Mausmodell zeigten die miRNAs
keine vergleichbaren Veränderungen oder Direktionalitäten wie bei humanen
Schlaganfallpatienten. In einer kombinierten Fluoreszenz-Hybridisierung mit
immunofluoreszenter Markierung von Zellen zeigte sich keine Kolokalisation der
Areale mit erhöhter miR-126-3p-Expression mit Neuronen oder Astrozyten.
Zusammenfassend haben thrombozytenassoziierte miRNAs großes Potential
als diagnostische Biomarker für den ischämischen Schlaganfall.
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AUC area under the curve
cDNA complementary DNA














FISH fluorescent in-situ hybridization
FLAIR fluid-attenuated inversion recovery
GFAP glial fibrillary acidic protein
ICAM intercellular adhesion molecule
IL-6 interleukin-6
ISD Institute for Stroke and Dementia Research
MACS magnetic activated cell sorting
MCA middle cerebral artery




8 LIST OF ABBREVIATIONS
miRNA microRNA
MRI magnetic resonance imaging
mRNA messenger RNA
NfL Neurofilament light protein
NGS normal goat serum
NSE Neuron-specific enolase
PBS phosphate-buffered saline






RISC RNA-induced silencing complex
ROC receiver operating characteristics
RT reverse transcription
RT-qPCR reverse transcription quantitative poly-
merase chain reaction
Scrbl scramble miRNA probe
SD standard deviation
SEM standard error of the mean
SMC smooth muscle cell
SSC saline sodium citrate
TBS Tris-buffered saline
TGF-b transforming growth factor beta
TIA transient ischemic attack
TNFa tumor necrosis factor alpha
TOAST Trial of Org 10172 in Acute Stroke Treat-
ment
tPA tissue plasminogen activator
UTR untranslated region
VCAM vascular cell adhesion molecule
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